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ABSTRACT 
Although its causes are not yet well defined, neurodegenerative diseases have been subject 
of intensive research in last decades in an attempt to understand the mechanisms underlying 
the neurodegeneration processes. The etiology of these diseases is multifactorial, being 
assumed that it involves a complex interaction between the (natural) aging, genetic 
predisposition and environmental factors. In many neurodegenerative diseases, one of the 
factors identified as responsible for their development is the alteration of homeostasis of some 
trace elements (TE) in certain areas of the brain. The main goal of the work reported in this 
dissertation was to study the age- and disease-related changes on TE levels in different 
anatomical regions of human brain.  
It was found that distribution of TE within brain tissue is not homogeneous. Iron is the most 
abundant metal, followed by zinc and copper. Zn higher levels were found in hippocampus 
and middle temporal region; higher levels of the other TE were found in basal ganglia. Pons 
and medulla were the regions with lower levels of four of the TE studied (iron, copper, 
manganese and zinc). In specific areas, TE levels seem to be age-related. A positive 
correlation between Cu and Zn levels and age was found, namely in middle temporal, 
caudate, putamen and cingulated gyrus. 
When compared with healthy people of the same age sub-group, TE levels from two 
individuals affected by Alzheimer’s disease were found significantly altered in regions mainly 
related to memory and learning. In one Alzheimer’s disease patient, 85 years old, high levels 
were found in hippocampus (Cu ↑2x; Fe ↑1,3x), middle temporal (Cu ↑1.4x), caudate (Fe 
↑1.7x; Mn ↑1.6x; Cu ↑1.9%; Zn ↑1.5x), and pons (Mn ↑1.7x, Cu ↑1.93x, Zn ↑1.2x). In the other 
Alzheimer’s disease patient, 73 years old, high levels of Fe in caudate (↑1,9x) and 
hippocampus (↑2,1x) were found. Low levels of Mn in hippocampus (↓0.6x) and cingulated 
gyrus (↓0.6x) and of Cu (↓0.4x) and Zn (↓0.7x) in cingulated gyrus were also found. 
In Parkinson’s disease, it was found that the regions affected by TE imbalances are mainly 
related to motor control but also to memory and learning: caudate (Fe ↑1.34x), putamen (Fe 
↑1.5x; Mn ↑3.3x; Cu -↓0.6x), globus pallidus (Fe ↑2.3x; Mn ↓0.6x), cingulated gyrus (Fe ↑1.5x; 
Mn ↑1.6x; Cu ↓0.6x), hippocampus (Fe ↑1.3x; Mn ↑1.4x; Zn ↑1.2x; Cu ↓0.70x) and midbrain 
(Mn ↑1,5x; Zn ↓0.8x).  
In amyotrophic lateral sclerosis, it were found lower Fe levels caudate (↓0.4x), putamen 
(↓0.4x) globus pallidus (↓0.6x), regions mainly connected to motor function. 
Keywords: trace elements; human brain levels; aging; neurodegenerative diseases; atomic 
absorption spectrometry; inductively coupled plasma-mass spectrometry. 
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RESUMO 
Apesar das suas causas ainda não estarem claramente definidas, nas últimas décadas as 
doenças neurodegenerativas tornaram-se um alvo de grande investigação, numa tentativa de 
compreender os mecanismos associados ao processo neurodegenerativo. A etiologia deste grupo 
de doenças é multifatorial, sendo assumido que envolve uma interação complexa entre fatores 
como envelhecimento natural, predisposição genética e fatores ambientais. Um dos fatores 
identificado como possivelmente envolvido na patologia das doenças neurodegenerativas é a 
alteração da homeostasia de alguns elementos vestigiais (EV) em determinadas regiões do 
encéfalo. 
O objetivo principal do trabalho apresentado nesta dissertação foi o estudo das alterações nos 
níveis de diversos EV no encéfalo humano relacionadas com o envelhecimento e os processos 
degenerativos. Constatou-se que a distribuição dos elementos analisados no encéfalo não é 
homogénea. O Fe mostrou ser o metal mais abundante, seguindo-se o Zn e o Cu. Os níveis mais 
elevados de Zn encontraram-se na região do hipocampo e lobo temporal; os níveis mais elevados 
de Cu, Fe e Mn foram encontrados nos núcleos da base. A ponte e a medula são as regiões 
cerebrais com menor teor dos quatro elementos referidos. Em algumas regiões do encéfalo a 
acumulação dos EV estudados parece estar associada ao envelhecimento uma vez que se 
encontrou uma correlação positiva entre os seus níveis e a idade, nomeadamente nas zonas do 
lobo temporal médio, caudado, putamen e cíngulo.  
Quando comparados com indivíduos da mesma faixa etária sem evidência de doença 
neurodegenerativa, observaram-se níveis de EV alterados em dois doentes de Alzheimer, 
nomeadamente nas regiões cerebrais associadas à memória. Num dos doentes, com 85 anos de 
idade, observou-se um aumento dos níveis de EV na zona do (Cu ↑2x; Fe ↑1,3x), temporal médio 
(Cu ↑1.4x), caudado (Fe ↑1.7x; Mn ↑1.6x; Cu ↑1.9%; Zn ↑1.5x), e ponte (Mn ↑1.7x, Cu ↑1.93x, Zn 
↑1.2x). No outro doente, com 73 anos, foi também observado um aumento dos níveis de EV no 
caudado (↑1,9x) e hipocampo (↑2,1x). No hipocampo observou-se ainda uma redução dos níveis 
de Mn (↓0.6x). No cíngulo foram encontrados níveis reduzidos de Mn (↓0.6x), Cu (↓0.4x) e Zn 
(↓0.7x). 
Num doente de Parkinson, encontraram-se níveis significativamente alterados dos EV no caudado 
(Fe ↑1.34x), putamen (Fe ↑1.5x; Mn ↑3.3x; Cu -↓0.6x), globus pallidus (Fe ↑2.3x; Mn ↓0.6x), giro 
cingulado (Fe ↑1.5x; Mn ↑1.6x; Cu ↓0.6x), hippocampus (Fe ↑1.3x; Mn ↑1.4x; Zn ↑1.2x; Cu ↓0.70x) 
e mesencéfalo (Mn ↑1,5x; Zn ↓0.8x).  
No doente com esclerose lateral amiotrófica foi observada uma diminuição dos níveis de Fe no 
caudado (↓0.4x), putamen (↓0.4x) e globus pallidus (↓0.6x), regiões principalmente associadas a 
funções motoras. 
Palavras-chave: elementos vestigiais; níveis no encéfalo humano; envelhecimento; doenças 
neurodegenerativas; espectrofotometria de absorção atómica; espectroscopia plasma-massa. 
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INTRODUCTORY NOTE 
In 2010, more than 500 million people were aged 65 or older, representing 8% of the 
world’s population. By 2050, this number is expected to nearly triplicate to about 1.5 
billion, representing 16% of the world’s population [1, 2]. According to Instituto Nacional 
de Estatística data, until 2050 one third of Portuguese population will be ≥ 65 years old 
and one million will be ≥ 80 years old [3]. 
According to 2011 census, in Portugal, 60% of people aged ≥ 65 years live alone or  with 
people with same age [3]. In addition, according to Polícia de Segurança Pública data, 
around 3000 elderly people were found dead at their homes in 2011 [4]. People with 
dementia living alone are exposed to risks that exceed the risks faced by people with 
dementia who live with family or a caregiver, including inadequate self-care, malnutrition, 
and lack of medical conditions, falls and accidental deaths. 
The rate of death related to neurological disorders dramatically increased by one- to two 
fold between 1979 and 1997 in the major western world countries, illustrating the 
significance of brain-related disorders in actual society [5]. In addition, it is estimated that 
‘‘brain-related disorders’’ represent 35% of the total economic burden of diseases in 
Europe, reaching a total of $386 billion, of which $135 billion are indirect medical costs [6]. 
Metal-induced oxidative stress has been considered to have a significant role in 
neurodegenerative diseases evolution, leading to the production of intracellular protein 
aggregates in neurons, and subsequent accumulation, reflecting cell incapacity to 
adequately respond to their formation.  
Despite of the intensive work that has been done in last decades on the relationship 
between trace elements and neurodegenerative diseases, the evidence is still 
fragmentary and these diseases remain poorly understood, which is reflected by the lack 
of disease modifying therapies. It is clearly urgent to clarify the causes and mechanisms 
involved in age-related processes and neurodegenerative diseases in order to improve 
therapeutic measures to slow down the onset of these disorders and/or to enable an 
effective delay of their onset. 
The present dissertation is structured in four main parts: 
I. Theoretical background, reviewing key scientific publications related to natural 
aging, neurodegeneration and the involvement of main trace elements in these 
processes.  
 
II. Objectives, presenting the specific goals of the work performed. 
xvi 
 
 
III. Experimental research, describing the experimental work in order to answer 
the questions formulated in the Objectives section. 
 
IV. Conclusions and future research, where the deductions from data obtained will 
be taken in the context of the proposed objectives. Complementary studies will 
be also projected. 
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I. THEORETICAL 
BACKGROUND 
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THEORETICAL BACKGROUND 
It is an old wisdom that metals are indispensable for life. However, the role of metals and 
their impact on life remained largely hidden until inorganic chemistry and coordination 
chemistry experienced a pronounced revival in the second half of the twentieth century 
[7]. The experimental and theoretical tools created in this period and their application to 
biochemical problems led to the development of bioinorganic chemistry or inorganic 
biochemistry, more recently also often named as biological inorganic chemistry. 
The development of biological inorganic chemistry during the past decades was, and still 
is, driven by attempts to understand the interaction between metal ions and 
macromolecules and clarify biological processes, to understand the accumulation, 
transport, metabolism and toxicity of metal ions and to develop metal-based drugs. 
The role of some metal ions was found to be particularly important in brain functions and 
has led to the introduction of metalloneurochemistry, the branch of biological inorganic 
chemistry dedicated to the study of metal ions in brain and nervous system at molecular 
level [8]. 
 
1.1.  THE IMPORTANCE OF TRACE ELEMENTS IN BRAIN FUNCTION 
About 50 of the known elements occur in measurable concentrations in the living systems 
but in humans and other mammals, only 23 elements have known physiological activities. 
For human health purposes, the essential elements can be sub-classified according to the 
concentration (trace or major) in which they are found in body fluids and tissues. 
According to the Clinical and Laboratory Standards Institute, elements are classified as 
major (concentrations above 10 mg/L in fluids; above 100 μg/g in tissues), trace (body 
content 0,01 to 100 μg/g; 10 to 104 μg/L) or ultratrace (body content less than 0,01 μg/g; 
less than 10 μg/L) [9]. For simplifying, in this work it will be consistently used the term 
trace element and no distinction will be made between the terms ultratrace and trace. 
Of the elements with known physiological activities, 11 can be classified as trace elements 
(TE). Most of TE are in the period 4 of the Periodic Table (Figure 1), suggesting an 
optimal relationship of nuclei size/electron availability of the elements in this period to 
interact with organic molecules present in biological systems [10]. TE include the 
transition metals vanadium (V), chromium (Cr), manganese (Mn), iron  (Fe), cobalt (Co), 
copper (Cu), zinc (Zn), and molybdenum (Mo) and the non-metals selenium (Se), fluorine  
(F) , and iodine (I).  
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Figure 1: Classification of elements based on Clinical and Laboratory Standards Institute [5]. 
 
In biological systems, metallic TE are mostly conjugated or bound to proteins, forming 
metalloproteins, or to smaller molecules (e.g. phosphates, polyphenols and other 
chelating compounds). Most of the metals in metalloproteins are part of enzymatic 
systems, have structural functions, or use the protein to be transported to their target site 
in the organism. In enzymes, metals participate in catalytic processes as constituents of 
enzyme active sites or stabilizers of enzyme tertiary or quaternary structure. As 
constituents of active sites, metal cations with unpaired electrons mediate oxidation–
reduction processes by reversible changes in their oxidation state, transferring or 
receiving electrons to or from the substrate and co-factor. For example, superoxide 
dismutases (SOD) reduce one superoxide anion (O2
●-) to hydrogen peroxide (H2O2), and 
oxidize a second O2
●- to generate molecular oxygen by either Cu or Mn present in the 
active site of the cytosolic or mitochondrial enzyme, respectively. The presence of metals 
bound to lipids, nucleic acids, and carbohydrates is well documented, but the biochemical 
functions of the metals present in these molecules is unclear [11].  
1.1.1.  IRON 
Iron (Fe) is the most abundant transition metal in the human body and has many essential 
functions in brain and nervous system. It is not only involved in oxygen transport, 
 Trace Toxic Major 
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mitochondrial respiration, protein and DNA synthesis, but also plays an important role in 
the formation of myelin and the development of dendrites [12]. Further, iron is involved on 
the biosynthesis of neurotransmitters such as dopamine, in axonal growth and in receptor-
mediated postsynaptic signal transduction [13].   
Fe is found in four classes of proteins: Fe-heme proteins (e.g. hemoglobin, myoglobin, 
catalase, cytochromes); Fe–sulfur enzymes (e.g. aconitase, fumarate reductase); proteins 
for Fe storage and transport (transferrin, lactoferrin, ferritin, hemosiderin), and other Fe-
containing or Fe-activated enzymes (e.g. NADH dehydrogenase, succinate 
dehydrogenase, alcohol dehydrogenase, cyclooxygenases) [12].  
In vivo, Fe is present in both the ferrous (Fe2+) and ferric (Fe3+) valence states. The ease 
with which ion converts between Fe2+ and Fe3+ is critical for metabolism. Its uptake and 
transport across membranes, and release from transporter proteins such as transferrin 
(Tf), is dependent on reduction to Fe2+. As the ferrous form is highly redox active (and 
thus more toxic), the majority of non-heme iron that is not immediately utilized is 
prevented from participating in harmful reactions through uptake, oxidation and storage in 
ferritin [14]. Free Fe is readily bound by Tf, and the 'supply and demand' response to the 
labile iron pool is thought to determine the expression of Tf receptors and ferritin to 
maintain iron homeostasis within the brain [12]. 
Fe is usually transported in plasma and other extracellular fluids bound to Tf and taken up 
by cells via the transferrin cycle (Figure 2). In plasma, at physiologic pH, holotransferrin 
(Tf-Fe (III)) binds to transferrin receptors (TfR) on the cell surface. The complexes localize 
to calathrine-coated pits, which invaginate to initiate endocytosis process. The calathrin 
coat is removed and specialized endosomes are acidified by an ATP-dependent proton 
pump. At the acidic pH the holotransferrin undergoes a conformational change and 
releases Fe (III), which is then converted to Fe (II) by an endosomal metalloreductase and 
transported out of the endosome into the cytosol by the divalent metal transporter-1 
(DMT1). Apotransferrin (ApoTf) bounds to its receptor, TfR, and is exocytosed by a 
recycling endosome to the plasma cell membrane, where, at neutral pH, the complex 
dissociates and proteins are able to participate in further rounds of iron delivery. Fe (II) 
can be stored in ferritin in non-erythroid cells or incorporated into hemoglobin in erythroid 
cells [15-17]. 
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Figure 2: The transferrin cycle: iron transport and storage [17]. 
 
Brain is protected by a poorly permeable vascular membrane, the blood-brain barrier, 
composed of endothelial cells in small vessels throughout the brain that contain tight 
junctions, which regulate the access of nutrients and other molecules [18]. In addition, 
fenestrated blood vessels in the choroid plexus that produce cerebrospinal fluid (CSF) 
also regulate brain Fe [19]. Under normal physiological conditions, the brain stringently 
regulates Fe balance by, possibly, three systems: (i) via TfR-mediated transport or the 
non TfR mediated transport at brain barriers; (ii) the Fe storage in which the cellular 
sequestration is largely dependent upon availability of ferritin; and (iii) the efflux of Fe 
whose rate is controlled by bulk CSF flow and/or by the removal mechanism in the blood-
CSF barrier back to the blood circulation [13]. Tf-bound Fe is the mainly primary species 
transported into the brain and this transport by blood-brain barrier may explain the unique 
Fe distribution pattern.  
Available data suggest that normal Fe content within the brain varies significantly from 
one region to another: greater concentrations are found in substantia nigra (SN), basal 
ganglia, hippocampus and subcortical brain regions [20]. Studies show that regions of the 
brain associated with motor functions tend to have a higher Fe content than non-motor 
related regions, which highlight the link between movement disorders and iron loading 
[21]. 
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Iron accumulation is a characteristic feature of several neurodegenerative diseases, such 
as Parkinson’s disease and Alzheimer’s disease, and also other rarer disorders like 
aceruloplasminemia, Hallervorden-Spatz disease (neurodegeneration with brain iron 
accumulation), Friedreich’s ataxia or neuroferritinopathy. Iron has been implicated in these 
diseases for its capacity to increase oxidative stress, and chelators ameliorate Parkinson-
like disease in animal models. However, its precise role in these disorders remains 
unclear. It is still not known whether abnormal iron metabolism leads to 
neurodegeneration or occurs as a consequence of neurons damage. 
 
1.1.2.  MANGANESE 
Manganese (Mn) is associated with bone development and with amino acid, lipid and 
carbohydrate metabolism. Mn plays an important role in a number of physiologic 
processes as a constituent of multiple enzymes (e.g. mitocondrial Mn-SOD, glutamine 
synthetase and arginase) and as an activator of other enzymes (several hydrolases, 
transferases and carboxylases) [22]. 
Mitochondria consume over 90% of the oxygen used by cells, which make this 
compartment especially susceptible to oxidative stress since it is a primary site of 
production of free radicals. The radical superoxide anion (O2
●-) is one of the reactive 
oxygen species (ROS) produced in mitochondria during ATP synthesis. Mn-SOD is the 
principal antioxidant enzyme in the mitochondria and catalyzes the conversion of O2
●- to 
H2O2, which can be further reduced to water by other antioxidant enzymes [12].  
In the brain, glutamine synthetase, after activation by Mn, converts the amino acid 
glutamate to glutamine. Glutamate is an excitotoxic neurotransmitter and a precursor to 
an inhibitory neurotransmitter, γ-aminobutyric acid (GABA) [23]. 
Although the specific mechanisms for Mn absorption and transport have not been 
determined, some evidence suggests that Fe and Mn can share common absorption and 
transport pathways. Because of their chemical similarity they share and compete for many 
protein transporters, such as DMT-1. As such, individual Fe status can affect Mn 
bioavailability: during of low Fe uptake conditions, abnormal Mn accumulation occurs. In 
addition, when Mn concentrations are altered, the Fe and other transition metals 
homeostasis are disrupted. [24] 
Mn intestinal absorption is increased during Fe deficiency, and increased Fe storage 
(ferritin levels) is associated with decreased Mn absorption [25]. Men generally absorb 
less Mn than women, which may be explained by the fact that men usually have higher Fe 
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stores than women [26]. Further, Fe deficiency has been shown to increase the risk of Mn 
accumulation in the brain, causing Parkinson-type syndrome, commonly referred as 
manganism or Parkinsonism [27, 28], mainly  in  areas  that  contain  higher  
concentrations  of nonheme  iron,  such as  basal ganglia, SN and  subthalamic  nuclei  
[29]. 
Manganism  is  initially  characterized  by  a  psychiatric  disorder (locura  manganica or 
manganese  madness) that  may  be  due  to  Mn acute  exposure,  causing  hyperactivity  
accompanied  by  elevated  brain levels  of  catecholamines  and  their  metabolites  [30]. 
Symptoms include compulsive and violent behavior, emotional instability, disorientation 
and hallucinations.  As  exposure  continues  and  the  disease  progresses, patients  may  
develop  prolonged  muscle  contractions, decreased  muscle  movement,  rigidity,    
muscle tremors and memory loss [31]. As occurs in Parkinson’s disease, these  signs  are  
associated  with  damage  of dopaminergic  neurons  within  brain  structures  associated 
to  muscle movement  control [32].  
There  has  been  some  controversy  about  the  alterations produced  by  Mn: some  
authors  found  that  Mn  modifies dopaminergic  functions  specifically  in  the  basal  
ganglia  and produces  Parkinson-like  disorder, while others  indicate  that  Mn  
intoxication  appears  to be  different  from  Parkinson’s disease  in  both  etiology  and  
pathology  particularly  in  the  notable  preservation of    SNC dopaminergic  somas [32]. 
 
1.1.3.  COPPER 
In humans, copper (Cu) is necessary for the development of connective tissue and bones, 
and for nerve myelination. It  is  also  involved  in  the  metabolism of neurotransmitters,  
and in regulation the  balance  of  other  metals in  the  body  such  as  zinc  and  
molybdenum [33].   
Though the majority of the body's copper is in the Cu2+ form, in the human body copper 
shifts between the cuprous (Cu+) and cupric (Cu2+) forms [34]. Like other transition metals, 
the ability of Cu to easily accept and donate electrons explains its important role in 
oxidation-reduction reactions and free radicals scavenging. 
Cu is a critical functional component of a number of essential enzymes such as Cu,Zn 
superoxide dismutase (Cu,Zn-SOD), lysil oxidase, dopamine hydroxylase, and several 
other oxidases that reduce molecular oxygen. As a cofactor in multiple redox reactions, 
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Cu is involved in the production of potentially damaging radical species through Fenton 
reaction [35].  
Several reactions essential to normal function of the brain and nervous system are 
catalyzed by cuproenzymes. Dopamine-β-monooxygenase catalyzes the conversion of 
dopamine (DA) to norepinephrine (NE). Monoamine oxidase (MAO) plays a role in the 
metabolism of the neurotransmitters DA, NE and epinephrine. MAO also acts in the 
degradation of the neurotransmitter serotonin, which is the basis for the use of MAO 
inhibitors as antidepressants [36]. Cu acts as a reductant in cytochrome c oxidase, that 
plays a critical role in cellular energy production: it catalyzes the reduction of molecular 
oxygen (O2) to water (H2O), generating an electrical gradient used by the mitochondria to 
create ATP [37]. Cytochrome c oxidase activity is also involved on phospholipids 
synthesis, the principal constituent of myelin sheath.   
After Cu has been taken up by the enterocytes it is exported to the bloodstream, in a 
process involving cytoplasmic transport to the membrane and exocytosis. Cu is then 
distributed to other tissues and is taken up by the cells. Once inside the cell, Cu 
homeostasis needs to be tightly regulated: the metal complexes with proteins to avoid the 
formation of deleterious hydroxyl radicals. Cu, bound either to albumin or histidine, 
crosses the plasma membrane via copper transport protein (Ctr1) or DMT-1. Inside the 
cell, Cu can suffer one of four possible fates: 1) it can directly enter the Cu metallothionein 
storage pool; 2) it can be transported to the mitochondria, for incorporation into the 
terminal oxidase of the respiratory chain, cytochrome c oxidase; 3) it can be incorporated 
into cytoplasmic Cu,Zn-SOD; or 4) it can be transported to the P-type ATPase located in 
the trans Golgi network for subsequent incorporation into ceruloplasmin [15, 38]. 
 
 
 
 
 
 
 
Figure 3: Model of copper transport in a hepatocyte [38]. 
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Two copper-containing enzymes, ceruloplasmin and ferroxidase II have the capacity to 
oxidize ferrous iron (Fe2+) to ferric iron (Fe3+), the form of iron that can be loaded onto 
transferrin for transport to the site of red blood cell formation. Although ferroxidase activity 
of these two cuproenzymes has not yet been proven to be physiologically significant, the 
fact that Fe mobilization from storage sites is impaired in Cu deficiency supports their role 
in iron metabolism [37]. Ceruloplasmin may function as an antioxidant in two different 
ways: binding Cu and preventing free Cu ions from catalyzing oxidative damage; and, 
once Ceruloplasmin has ferroxidase activity, the oxidation of ferrous iron facilitates Fe 
loading onto transferrin and may prevent free Fe2+ from participating in harmful free 
radical generating reactions [15]. 
Adequate Cu nutritional status appears to be necessary for normal Fe metabolism and red 
blood cell formation. Anemia is a clinical sign of Cu deficiency, and Fe has been found to 
accumulate in the liver of Cu deficient animals, indicating that Cu is required for Fe 
transport to the bone marrow for red blood cell formation. Infants fed with a high iron 
formula absorbed less copper than infants fed with a low iron formula, suggesting that 
high iron intake may interfere with copper absorption [39]. 
 
1.1.4.  ZINC 
Numerous aspects of cellular metabolism are zinc-dependent. Zinc (Zn) plays important 
roles in growth and development, immune response, neurological function and 
reproduction. Zinc is found at high levels in the brain, where it performs catalytic, 
structural and regulatory roles in cellular metabolism [15]. 
About a hundred of different enzymes (e.g. RNA polymerase, carbonic anhydrase, Cu,Zn-
SOD, angiotensin I converting enzyme) depends on Zn for their ability to catalyze vital 
chemical reactions. 
Zn plays an important role in the structure of proteins and cell membranes because its 
loss from biological membranes increases their susceptibility to oxidative damage and 
impairs their function [40] . A finger-like structure, known as zinc finger motif, stabilizes the 
structure of a number of proteins. For example, Cu provides the catalytic activity for the 
antioxidant enzyme Cu,Zn-SOD while Zn plays a critical structural role [39]. 
Zn finger proteins have been found to regulate gene expression by acting as transcription 
factors (binding to DNA and inducing specific genes transcription). Zn also plays a role in 
cell signaling and has been found to influence hormone release and nerve impulse 
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transmission. Zn has been found to play a role in apoptosis, a critical cellular regulatory 
process with implications for growth and development, as well as a number of chronic 
diseases [41].  
Besides its structural and catalytic role in several enzymes, Zn has a unique location and 
function in CNS. According to previous studies, Zn is not uniformly distributed throughout 
the brain. It is found at higher concentrations in certain regions such as the hippocampus 
and cortex and in lower amounts in cerebellum [42].  Zn is bound to proteins but free zinc 
(10% of total brain Zn) is distributed thought the CNS in synaptic vesicles of glutamatergic 
neurons and performs a role in neurotransmission mediated by glutamate and GABA [12]. 
Upon stimulation, both glutamate and Zn are released into the synapse and Zn is thought 
to play a role in stabilizing the neurotransmitter. At the synapse level, Zn reaches high 
concentrations and enters post-synaptic neurons via calcium channels, competing with 
calcium [42]. 
Normally, when entering post-synaptic neurons, Zn will be captured by methallotionein 
(MT) proteins. The binding of Zn to MT is one of the most important mechanisms of Zn 
homeostasis. 
Although there is a good correlation between Zn specific staining and neuronal death, the 
mechanism involved in Zn-induced neuronal degeneration is not completely elucidated. 
Increasing evidence suggests that Zn induces cell death by impairing proper mitochondrial 
function through different mechanisms, including inhibition of electron transport chain,O2 
consumption and energy production and induction of mitochondrial depolarization  [43-46]. 
Other studies have reported that elevated intracellular Zn inhibits glyceraldehyde-3-
phosphate dehydrogenase and phosphofructokinase, with consequent reduction of its 
downstream intermediates and a decrease in ATP intracellular concentrations [47]. All 
together, the evidences suggest that Zn decreases cell energy production. 
Unlike Cu and Fe, Zn has no unpaired electrons which prevents its participation in redox 
reactions. Zn act as an antioxidant since it is a constituent of Cu,Zn-SOD (both 
intracellular and extracellular). Plus, Zn can act as an antioxidant by: (i) inducing MT 
synthesis, which can bind redox active metals and scavenge ●OH via their cysteine 
groups; and (II) binding to sites in the membrane that otherwise could bind redox active 
metals [42, 48]. 
High supplemental Zn intakes for extended periods of time may result in Cu deficiency, 
which may be explained because Zn increases the synthesis of MT in intestinal cells, and 
these proteins bind several metals and prevent their absorption by trapping them in 
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intestinal cells. MT has a stronger affinity for Cu than for Zn, so high levels of MT induced 
by Zn excess cause a decrease in Cu absorption. In contrast, high Cu dietary intakes 
have not been found to significantly affect Zn nutritional status [39]. 
Even short-term deficits of Zn have been shown to impair certain measures of mental and 
neurological function while long-term deficits of Zn, especially during gestation, results in 
malformation and deficits in attention, learning, memory or neuropsychological behavior 
[12].  
 
1.2. TRACE ELEMENTS AND NEURODEGENERATIVE DISEASES 
Although transition metals are important for life, it has been evidenced their direct or 
indirect involvement in neuronal damage in many neurodegenerative disorders. 
Neurodegenerative diseases (ND) associated with the disruption of brain metal 
homeostasis include Alzheimer’s disease (AD),Parkinson’s disease (PD) and amyotrophic 
lateral sclerosis (ALS), Acquired hepatocerebral degeneration, Hungtington’s disease and 
Wilson’s disease. It has been observed that patients with ND accumulate metals in their 
nervous system, suggesting a role of metals in those disorders. Furthermore, there is an 
increasing recognition that these diseases are associated with localized accumulation of 
metal ions and oxidative stress in disease-affected regions [49].  
Abnormalities of metal ion biochemistry in neural tissue are associated with two key 
mechanisms: protein aggregation mediated by metal ions and oxidative reactions 
catalyzed by redox-active metals (Table 1) [7]. 
Table 1: Neurodegenerative disorders with possible metal-associated pathology. 
Neurodegenerative disease Implicated metal  Implicated proteins 
Alzheimer’s disease Copper, iron, zinc 
Amyloid-β, amyloid-β precursor 
protein 
 
Parkinson’s disease Iron 
α-synuclein, neuromelamin, 
ceruloplasmin, divalent cation 
transporter 
 
Amyotrophic lateral sclerosis Copper, zinc 
Cu,Zn-Superoxide dismutase 
 
Acquired hepatocerebral 
degeneration 
Manganese  
Huntington’s disease Iron 
Huntingtin 
 
Wilson’s disease Copper 
Ceruloplasmin, Wilson’s 
protein 
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Biological systems have developed tightly mechanisms for metal regulation at both the 
systemic level of absorption and distribution as well as at the cellular level of storage, 
recycling and utilization, so that the organism meets metabolic demand without over 
accumulation [49]. Excess metal not correctly stored by store vesicles or bounded to 
protein transport, it becomes available for potentially toxic reactivity. One of the dangers of 
redox-active metals like Fe and Cu is their ability to promote the formation of highly toxic 
hydroxyl radicals that oxidize biomolecules, leading to cell death [49]. Even in the absence 
of redox activity, metal cations like Zn2+ may also cause damage by inducing abnormal 
protein aggregation [50]. 
As discussed early, transition metals such as Fe and Cu facilitate the generation of free 
radicals in vivo [51].  The reaction between reduced transition metals, typically Fe (II) or 
Cu (II), and H2O2 (Fenton reaction) is particularly harmful, as it yields the hydroxyl radical, 
a highly reactive oxidative species with a limited diffusion distance [52].  
There are several factors inducing the pathological depositions, and, in general, neuronal 
death in neurological disorders appears to be multifactorial. However, it is clear that the 
underlying factor in neurological disorders is increased oxidative stress substantiated by 
findings showing that protein side-chains are modified either directly by ROS or reactive 
nitrogen species (RNS), or indirectly by products of lipid peroxidation [53]. 
The increased level of oxidative stress in AD brain is reflected by an increase of  Fe and 
Cu brain content, both capable of stimulating free radical formation, increased protein and 
DNA oxidation, enhanced lipid peroxidation and decreased level of cytochrome c oxidase 
[53].  
Various biochemical and physiological characteristics of the mammalian CNS are 
particularly vulnerable to redox-related damages, such as: I) the strong flux of molecular 
oxygen in normally-respiring neural tissues, II) excessive generation of ROS by 
mitochondria in aging post-mitotic neurons, III) susceptibility of CNS to lipid peroxidation 
accruing from its high cholesterol and unsaturated fat content, IV) the abundance of 
oxidizable (e.g. dopamine) and potentially-excitotoxic neurotransmitters (glutamate) [20]. 
Under normal conditions, free radicals are produced in the normal course of intermediary 
metabolism by some enzyme-catalyzed reactions, involving enzymes such as xanthine 
oxidase, cyclooxygenase or cytochrome P450, and are rapidly detoxified by defense 
systems. 
Free radicals are molecules containing one or more unpaired electrons, which are 
responsible for its considerable degree of reactivity. The most important group of radicals 
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generated in living systems represents the derived from oxygen, including the O2
•- [54]. 
The superoxide radical, considered as the ‘‘primary’’ ROS, is capable of further interaction 
with other molecules generating ‘‘secondary’’ ROS. This could be achieved either directly 
or prevalently through enzyme- or metal-catalyzed processes. The O2
•- itself is not 
particularly reactive because it does not react directly with polypeptides, sugars or nucleic 
acids but it is the precursor of much more reactive radicals. The addition of a second 
electron to O2
•- origins the peroxide ion O2
2-, which is not a radical, but at neutral pH 
values it will be protonated, producing hydrogen peroxide (H2O2):  
2 O2
2- + 2H+  H2O2 + O2       [Equation 1] 
The one-electron reduction of H2O2, also known as Fenton reaction, produces the highly 
reactive hydroxyl radical (●OH), which can react with a wide number of cellular 
constituents. The sum of the Fenton reaction (Equation 2) and reduction of Fe3+ reaction 
by superoxide (Equation 3) leads to the production of molecular oxygen,●OH and hydroxyl 
anion (OH-) (Haber-Weiss reaction; equation 4) in the presence of catalytic amounts of 
iron. 
Fe2+ + H2O2  Fe
3+ + ●OH + OH-      [Equation 2] 
Fe3+ + O2
•-   Fe2+ + O2        [Equation 3] 
O2
•- + H2O2  O2 + 
●OH + OH-      [Equation 4] 
 
In addition to ROS, reactive nitrogen species (RNS) are also generated. Immune system 
cells produce both O2
•- and NO during the oxidative burst triggered by inflammatory 
processes. Under these conditions, NO and O2
•- may react together to produce significant 
amounts of peroxynitrite anion (ONOO-), a much more oxidatively active molecule, which 
is an oxidizing free radical that can cause DNA fragmentation and lipid oxidation [53]: 
NO● + O2
●-  ONOO-        [Equation 5] 
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1.2.1. ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by a 
progressive and non-reversible neurological disorder causing cognitive and behavioral 
impairment. In the first stages of the disease, people experience memory loss and 
confusion, which may be mistaken with the memory changes that are sometimes 
associated with natural aging. The symptoms gradually lead to behavior and personality 
changes, a decline in cognitive abilities (such as decision-making and language skills, and 
people recognition ability) and motor functions [55].  
According to the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Association, the diagnosis of AD requires clinical evidence of 
memory impairment (learn new information or to recall previously learned information) and 
impairment of at least one other cognitive domain with evidence of disturbance in social or 
occupational function: loss of word comprehension ability (aphasia); loss of ability to 
perform complex tasks involving muscle coordination (apraxia); loss of ability to recognize 
and use familiar objects (agnosia); loss of ability to plan, organize, and execute normal 
activities) [56] . 
Despite all the research performed, the precise physiological changes responsible for 
trigger the development of AD largely remain unknown. Exceptions are certain rare, 
inherited forms of the disease, caused by known genetic mutations. Since until today 
there is no effective prevention or treatment for AD, the increasing prevalence of dementia 
is a matter of public health and social concern [57]. 
 
1.2.1.1. EPIDEMIOLOGY 
AD constitutes approximately 70% of all dementia cases [58]. Currently affects over 35 
million people worldwide and its prevalence is estimated to nearly double every 20 years, 
reaching more than 55 million people in 2030 and 115 million in 2050 [59].  
Incidence of AD increases with age, doubling every five to ten years: for persons aged 
65–69, 70–74, 75–79, 80–84, and > 85 years the incidence of AD has been estimated as 
0.6%, 1.0%, 2.0%, 3.3% and 8.4%, respectively [60]. Prevalence also increases 
exponentially with age, rising from 3% among in 65–74 years old individuals, to almost 
50% on those aged 85 or older [60, 61]. The major risk factor for AD is age and the odds 
of receiving the diagnosis of AD after 85 years of  age  exceed  one  in  three [62]. 
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According to USA population data, more women than men have AD and other dementias, 
which is primarily explained by the fact that on average women live longer than men. 
Some studies on the age-specific incidence of AD or any other dementia have found no 
significant difference between sex at any given age [63]. Other studies support the theory 
that females are more susceptible to AD due to higher constitutive activity of the synaptic 
zinc transporter (ZnT3). Female mice exhibited age-dependent hyperactivity of this 
transporter, which was associated with increased amyloid-β, the main component of 
amyloid plaques associated with this disease [64]. Another hypothesis for higher 
prevalence in woman could be related to post-menopausal oestrogen deficiency, but the 
mechanism remains unclear [65]. Oestrogen seems to have anti-amyloidogenic effects, 
neurotrophic, neuroprotective and antioxidant properties. 
 
1.2.1.2. ETIOLOGY  
Sporadic AD accounts for approximately 95% of all AD cases and results from a complex 
array of biomolecular cascades that aggregate to produce cognitive decline, severe 
memory impairment, and ultimately death. These cascades initially occur in 
mediotemporal region, before spreading cortically outward to the neocortex [51]. The 
other 5% of total AD cases are related to genetic causes. This particular form of disease, 
also known as familial AD, is caused by rare mutations in the genes coding for three 
proteins – β-amyloid precursor protein (APP), presenilin-1 (PS-1) and presenilin-2 (PS-2) 
– associated with the abnormal production or clearance of Aβ [66] . 
Despite differing in their causes and ages of onset (40–60 years old for the familial AD; ≥ 
65 years old for the sporadic AD), their pathophysiological end-products are quite similar 
[55]. And in both cases, the disease causes progressive loss of memory and thinking 
ability, mood swings, personality changes and loss of independence.  
The cause or causes of AD are not yet known. However, it is agreed that AD, like other 
common chronic diseases, develops as a result of multiple factors rather than a single 
cause. Age, family history of dementia, head trauma, environmental factors, genetic 
factors, female gender, low education level, cardiovascular disease and diet are risk 
factors assumed to be involved on AD onset [55, 63].  
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1.2.1.3. PATHOLOGY 
Macroscopically, brains of individuals with AD are atrophic, about 8–15% smaller than 
age-matched controls, with widened sulci and narrowed gyri, due to massive loss of 
neurons and disruption of synaptic function [55]. It seems to exist a regional susceptibility 
since the pathological hallmarks of the disease are most frequently found within the 
association regions of the hippocampus and temporal lobe, which play a key role in 
formation of new memories [67]. Degeneration of selective hippocampal regions 
contributes to functional isolation of the hippocampus, resulting in to the marked short-
term memory impairment evident in the early stages of the disease [55]. Neuronal 
damage may also affect the parietal and frontal lobes and the white matter volume is 
reduced, leading to an enlargement of the temporal horns of the lateral ventricles [68].   
The most common and distinctive lesions present within the diseased brain are the senile 
plaques with β-amyloid peptide and neurofibrillary tangles. These findings are the chosen 
lesions to confirm the diagnosis of AD at autopsy exam [55]. Widespread oxidative stress, 
neuroinflammation, calcium dysregulation and mitochondrial malformation and amyloid-β 
oligomerization are found in AD patients [51]. Neuronal and dendritic loss, neuropil 
threads, dystrophic neurites, granulovacuolar degeneration, Hirano bodies and 
cerebrovascular amyloid angiopathy are also typical findings of the AD brain but are less 
specific findings [55]. 
β-amyloid (Aβ) peptides are natural products of metabolism consisting of 39 to 43 amino 
acids cleaved from the C-terminal region of the amyloid precursor protein (APP) by the 
sequential enzymatic actions of β-site amyloid precursor protein–cleaving enzyme 1 
(BACE-1) and γ-secretase [69]. Monomers of Aβ40 are more abundant than the 
aggregation-prone and neurotoxic Aβ42. An imbalance between production and 
clearance, and aggregation of peptides causes Aβ accumulation, which can be 
responsible for the onset of AD. This is is the so-called “amyloid hypothesis”. 
Neurofibrillary tangles (NFTs) are filamentous inclusions in pyramidal neurons which main 
component is an abnormally hyper-phosphorylated and aggregated form of Tau protein. 
Normally an abundant soluble protein in axons, Tau promotes the assembly and stability 
of microtubules and vesicle transport. Hyperphosphorylated Tau is insoluble, lacks affinity 
for microtubules, and self-associates into paired helical filament structures. As Aβ 
oligomers, intermediate aggregates of Tau molecules are cytotoxic and impair axonal 
transport and, consequently, cognition [69]. 
The accumulation  of  these misfolded  proteins in the aging brain results in oxidative and 
inflammatory damage, which  in turn leads to energy failure and synaptic dysfunction [62]. 
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Despite an extensive understanding of each of these phenomena individually occurs 
within the cell, an explanation for their origin, interaction and evolution as related to AD is 
lacking.  
It is known that oxidative stress undoubtedly plays a critical role, as evidence for its impact 
at a molecular level exists very early in the disease progression and Aβ confers striking 
neurotoxicity to neurons and is certainly an important aspect of the disease [70, 71]. Aβ is 
toxic for mitochondria, affecting particularly the synaptic pool [72]. In AD, exposure to Aβ 
inhibits key mitochondrial enzymes, as cytochrome c oxidase, in the brain [73]. 
Consequently, electron transport, ATP production, oxygen consumption and mitochondrial 
membrane potential all become impaired. The increase in mitochondrial O2
●- formation 
and conversion into H2O2 cause oxidative stress, release of cytochrome c and apoptosis. 
Notably, oxidative stress and Aβ accumulation share a common starting factor: reactive 
transition metal aberration. Increased oxidative stress, the impaired protein-folding 
function of the endoplasmic reticulum, and deficient proteasome-mediated and autophagic 
mediated clearance of damaged proteins, all of which are also associated with aging, 
accelerate the accumulation of amyloid and Tau proteins in AD [74]. 
 
1.2.1.4. TRACE ELEMENTS INVOLVEMENT IN ALZHEIMER’S DISEASE 
Imbalances in Al, Si, Pb, Hg, Zn, Fe and Cu have been reported in AD, and the latter 
three are known to be elevated in AD neuropil, suggesting their importance in disease 
pathogenesis [75]. Furthermore, in situ iron detection has revealed a marked association 
between redox-active Fe and both NFTs and Aβ-rich senile plaques [2]. The association 
between Aβ and transition metals such as Fe and Cu may also lead to the generation of 
H2O2, exacerbating the oxidative damage [76]. 
There is evidences suggesting that also altered Cu homeostasis exists in AD and that 
such alteration can lead to a redox imbalance by altering the functioning of important 
enzymes like Cu,Zn-SOD, cytochrome c oxidase and ceruloplasmin [57]. Zn is also known 
to accumulate in high concentrations within the core and peripheral areas of senile 
plaques such that tissue exposure to metal-selective chelators prevents lesion detection 
[52].  
Differences in brain metal homeostasis between individuals could therefore influence risk 
of developing AD via a number of routes: such as by increasing Aβ production, by 
facilitating Aβ aggregation and fibrillation, by altering the availability of metals for 
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catalyzing essential enzyme reactions, or conversely generating toxic reactive oxygen 
species [65]. 
There is evidences suggesting that altered Cu homeostasis also exists in AD and that 
such alteration can lead to a redox imbalance by altering the functioning of important 
enzymes like Cu,Zn-SOD, cytochrome c oxidase and cerulopasmin [57]. Zn is also known 
to accumulate in high concentrations within the core and peripheral areas of senile 
plaques such that tissue exposure to metal-selective chelators prevents lesion detection 
[52].   
Differences in brain metal homeostasis between individuals could therefore influence risk 
of developing AD via a number of mechanisms: increasing Aβ production, facilitating Aβ 
aggregation and fibrillation, altering the ability of metals for catalyzing essential enzymatic 
reactions; or conversely generating toxic reactive oxygen species [65]. 
 
1.2.1.4.1. COPPER HOMEOSTASIS IN ALZHEIMER’S DISEASE  
Evidence suggests that AD development involves an altered Cu homeostasis. Some 
studies support the idea that Cu participates in the development of AD as a noxious metal, 
since high levels of Cu have been found in amyloid plaques from AD patients [75, 77]. 
Other studies suggest that Cu may prevent both the formation and the accumulation of βA 
plaques in vitro, reducing amyloidogenesis [78, 79]. In the transgenic murine model of AD, 
exposure to Cu in the drinking water produced the exacerbation of Aβ and Tau pathologic 
consequences [80], suggesting that Cu may be influencing not only the senile plaque, but 
also the neurofibrillary tangles. It should be noted that the Aβ involved in the pathogenesis 
of AD show high affinity for Cu [81]. Cu binding promotes Aβ toxicity through the formation 
of H2O2 and the subsequent generation of free radicals through the Fenton reaction [82, 
83] involving Cu (II) reduction by Aβ [76, 82]. Consequently, a cascade of events related 
to oxidative stress, ROS production and subsequent neuronal death occurs (Figure 4). It 
has been reported that the Aβ inhibits the cytochrome c oxidase complex of the 
mitochondrial electron transport chain and other studies indicate that this inhibition may be 
further increased by the presence of Cu (II) ions. This effect may be due to the ability of 
the Aβ-Cu complex to generate H2O2 and also to the formation of an intermediate reactive 
product that interacts with cytochrome c oxidase [84].   
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Figure 4: Oxidative stress and mitochondrial failure [69].  
Aβ is linked to ROS and RNS production. Their peroxidative attack on cell and organelle membrane lipids 
yields mitochondrial toxins such as hydroxynonenal (HNE) and malondialdehyde. Oxidative damage to 
membrane-bound, ion-specific ATPases and stimulation of calcium (Ca
2+
) entry mechanisms cause cytosolic 
and mitochondrial Ca
2+
 overload. Cellular Aβ directly attacks electron transport complex IV (cytochrome c 
oxidase) and key tricarboxylic acid cycle (α-ketoglutarate and pyruvate dehydrogenase) and damages 
mitochondrial DNA (mtDNA),  leading to its fragmentation. Lipid peroxidation products also promote Tau 
phosphorylation and aggregation, which in turn inhibit complex I. High amounts of ROS and RNS are 
generated at complexes I and III. As the mitochondrial membrane potential (MPP) collapses and permeability-
transition pores (ψm) open, caspases are activated. Aβ also induces the stress-activated protein kinases p38 
and c-jun. Substrate deficiencies, notably NADH and glucose, combine with electron transport uncoupling to 
further diminish ATP production.  
 
In glutamatergic neurotransmission Cu is co-released with glutamate and substantial 
amounts of Cu ions, susceptible to bind to Aβ (coming from the action of secretases on 
APP), can be found in the synaptic space [85], enhancing Aβ oligomerization and 
precipitation and consequently the formation of senile plaques (Figure  5). 
Although its function is not completely known, it has been suggested that APP-Aβ may act 
as a Cu carrier system since APP knockout mice showed an increased Cu content in the 
cortex as compared to wild-type animals [86], what could explain why Cu deficiency down-
regulates APP transcription [87] and the Aβ’s high affinity for copper [81]. Cu also 
interacts with APP in an electron transfer reaction that reduces Cu (II) to Cu (I), enhancing 
the production of hydroxyl radical [77].  
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In contrast, evidence supporting a Cu deficiency in AD is based on findings showing Cu 
concentration in the cerebrospinal fluid (CSF) from AD patients inversely correlated to Aβ 
[88]. In addition, it has been demonstrated that Cu deficiency can elevate βA peptide 
secretion by either influencing APP cleavage or inhibiting its degradation [89]. 
Cu deficiency may also influence the activity of Cu-binding proteins in AD. It has been 
observed a reduced Cu,Zn-SOD activity in CSF from AD patients when compared to 
controls, as well as the activity of cytochrome c oxidase [90]. Ceruloplasmin, a 
multicopper ferroxidase necessary for the oxidation of Fe2+ to Fe3+ and subsequent 
binding of Fe to transferrin, could be an important factor in AD because in this protein 
converge both Cu and Fe homeostasis [57]. However, there are conflicting reports in the 
literature. Some studies report significantly increased Ceruloplasmin levels in most brain 
regions of AD patients compared to elderly controls [91], whereas, decreased levels were 
found in temporal cortex [57]. Serum levels of both Cu and Ceruloplasmin were 
significantly higher in AD patients and both Ceruloplasmin ferroxidase and Cu,Zn-SOD 
activities have a tendency to be decreased in CSF when compared with controls [92]. Cu 
deficiency also results in higher ROS production and oxidative damage to proteins.  
Although many questions remain unanswered, it is widely accepted that in AD there is an 
abnormal brain Cu distribution with accumulation in amyloid plaques and a deficiency of 
Cu in adjacent cells [78] but further investigations are needed to fully understand its dual 
role in AD. All the evidence suggests that altered Cu homeostasis is present in AD and 
that such alteration can lead to a redox imbalance by altering the functioning of important 
enzymes, namely Cu,Zn-SOD and Ceruloplasmin. 
  
1.2.1.4.2. IRON HOMEOSTASIS IN ALZHEIMER’S DISEASE 
Fe is involved in the pathophysiology of AD as suggested by its presence in senile 
plaques and neurofibrillary tangles of AD patients brain [75]. Fe has been associated with 
free radical generation through Fenton reaction, leading to the formation of the highly 
reactive hydroxyl radical (●OH) which damages cell molecules such as membrane lipids, 
proteins and nucleic acids. Hydroxyl radical also seems to contribute to Aβ aggregation by 
promoting covalent binding between peptide monomers [93] 
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Figure 5: Cu and Fe homeostasis in Alzheimer’s disease [57].  
(1) Cu ions in the synaptic space are co-released with glutamate. Aβ, produced from APP by secretases, has 
high affinity for Cu. Aβ and Cu ions coincide in synaptic space, possibly inducing the precipitation of Aβ. (2) 
Cu is suspected to consolidate the formation of senile plaques by catalyzing new covalent bonds among 
polypeptides. Cu is found in high quantities in amyloid plaques. (3) Intracellular Cu is involved in the 
expression of matrix metalloproteinase responsible for the cleavage of Aβ. (4) High levels of Fe are involved in 
increased expression of APP through an Iron Response Element (IRE), whereas depletion of Cu decreases 
the expression of this protein. (5) Cu binding to Aβ increases the production of free radicals by itself and by 
inhibition of mitochondrial respiratory chain.  
 
The role of Fe in this disorder is supported by studies linking hereditary hemochromatosis 
to AD [94] and the presence of an Iron Responsive Element in the untranslated region of 
the APP gene [95]. Additionally, studies show that ferritin is also present in the brain 
senile plaques of patients with AD [57]. It was also found a positive correlation between 
Fe levels in the hippocampus and mental state of AD patients, supporting an important 
role for Fe in this ND [96]. 
 
1.2.2. PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a neurodegenerative brain disorder that progresses slowly in 
most people. It is characterized by motor manifestations (e.g., tremor, bradykinesia and 
muscle rigidity) but cognitive and behavioral abnormalities also occur [97, 98]. Aside  from  
classical  motor  deficits,  various  non-motor  symptoms  including  autonomic  
dysfunction, sensory  and  cognitive  impairments  as  well  as  neuropsychiatric  
alterations, pain  and  sleep  disturbances  are common  in  PD.  Some  of  these  non-
motor  symptoms  can  even  manifest before  motor  problems [99]. 
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1.2.2.1. EPIDEMIOLOGY 
PD is the second most common neurodegenerative disease after Alzheimer’s disease, 
affecting 7 to 10 million people worldwide [100]. PD has a prevalence of 0.5-1% among 
people older than 65 years of age which increases to 1-3% in the population over 80 
years of age [101]. Incidence of PD increases with age, but an estimated 4% of people 
with PD are diagnosed under 50 years of age [100].  
Statistics indicate that PD seems to affect man at a higher rate (1,5 times higher) than 
woman [100]. Possible reasons for this increased PD risk in man are toxicant exposure, 
head trauma, neuroprotection by oestrogen, mitochondrial dysfunction or X-linkage of 
genetic risk factors [15].  
 
1.2.2.2. ETIOLOGY 
Although the etiology of this selective neurodegeneration is still unknown, several genetic 
and environmental factors such as occupational exposure to transition metals and 
pesticides, have been implicated on the development of PD [97, 102, 103].  
Several studies support the role of brain transition metal accumulation in the 
pathophysiology of PD that may be independent of the environmental exposure, 
suggesting that metal homeostasis is altered in PD [57]. 
 
1.2.2.3. PATHOLOGY  
The pathology of PD is not fully understood. Between the fifth and the ninth decade of life 
the number of nigral cells in normal brain is reduced by 4.7-6% per decade, but this is not 
sufficient to cause PD itself [104]. 
Macroscopically, the SN and the locus coeruleus of PD brains are pale, reflecting loss of 
the normal pigment-bearing neurones. Microscopically, in addition to neuronal loss, large 
eosinophilic neuronal inclusions (Lewy bodies) can be seen displacing neuromelanin in 
these regions [68]. At the cellular level, severe loss of dopaminergic nerve cells in the 
substantia nigra pars compacta (SNpc) in the midbrain region and in the striatum (caudate 
nucleus and putamen) is linked with PD [105]. When manifestations of PD are fully 
developed, around 80% of dopaminergic neurons in the SN are already lost, resulting in 
reduced synthesis and release of DA from the striatal nerve terminals [106]. 
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The specific death of dopaminergic neurons in SNpc has also drawn attention towards a 
melanin like pigment, neuromelanin (NM), present in these cells. NM can bind metal ions, 
thus playing a protective role against cellular damage resulting from oxidative processes, 
which is compromised in PD, leading to death of dopaminergic cells in SN [105]. 
Besides dopamine neuronal degeneration, PD is characterized by cytoplasmic intrusions 
in some surviving nigral dopaminergic neurons, the Lewy bodies. The principal protein 
component of the Lewy bodies is α-synuclein, a small cytosolic protein ubiquitously 
expressed throughout the brain. Recent studies have shown that α-synuclein is able to 
interact with Zn, Cu and Fe, and that these interactions lead to protein aggregation and 
crosslinking [107]. 
 
1.2.2.4. TRACE ELEMENTS IN PARKINSON’S DISEASE 
The scenario of the PD is still not entirely clear, but a consensus is rising on oxidative 
injury co-factor of the neurodegenerative process. In this context, metals cannot be 
disregarded because of their key role in the intracellular oxidative equilibrium both as pro-
oxidant agents and as part of the antioxidant enzymes.  
In fact, the SN of PD subjects showed a high content of Fe, which is considered to 
catalyze, via Fenton reaction, the production of free radicals and to increase the rate of 
dopamine auto-oxidation, as well as the deposition of intracellular inclusion bodies, both 
characteristic features of the disease [57]. Cu and Mn can participate in the same reaction 
and displace Fe from its complex with NM, thereby increasing free Fe in the cytoplasm 
[108]. Although the neurotoxic potential of Fe has been consistently reported, evidence of 
Cu toxicity is not completely conclusive [57]. 
Zn is also reported to be increased and Cu decreased in SN of PD patients. In addition, 
Al, Cd, Cr and Hg are able to increase the susceptibility to the oxidative damage or 
interfere with detoxifying enzymes.  
 
1.2.2.4.1. Iron HOMEOSTASIS in Parkinson’s disease  
Post-mortem analysis of PD brains showed total Fe levels to be increased in SNpc but not 
in cerebellum, caudate nucleus, putamen or cerebral cortex [109], suggesting that the 
underlying mechanisms of Fe accumulation maybe specific for SNpc. In contrast, levels of 
this metal were found reduced in globus pallidus [57]. However, non-significant difference 
in Fe content has been found in brain tissue showing moderate neurodegeneration [94]; 
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thus, it could be considered that Fe accumulation in PD may be the consequence of the 
underlying mechanisms of neuronal death. Otherwise its levels should be expected to be 
increased since the early stages of the disorder; thus, some mechanisms may initiate 
neuronal death at the early stages of the disorder and lead to Fe accumulation that may 
potentiate oxidative damage [57]. 
Brain Fe levels increase during normal ageing and it is associated with a reduced motor 
performance [110]. Although Fe accumulation in PD is not explained by ageing itself, 
ageing seems to modulate Fe neurotoxicity [57]. Adult mice fed with Fe during the 
neonatal period showed reduced striatal dopamine levels while young mice have 
unchanged dopamine levels following the same treatment [97]. However, although brain 
Fe accumulation in young animals is not likely to produce neuronal death by itself, early 
postnatal Fe administration potentiates dopamine depletion during adulthood, suggesting 
that Fe accumulation in young animals may lead to neurotoxicity [111]. 
Fe brain levels in PD are higher than the expected by normal ageing and the underlying 
mechanism for such accumulation remains to be elucidated. Excitotoxicity may be 
involved in PD and may lead to Fe accumulation. Fe uptake is enhanced by N-Methyl-D-
Aspartate (NMDA) receptor activation through NO signaling [112]. Both glutamate and NO 
are involved in excitotoxic death suggested in PD (Figure 6); thus, Fe accumulation in this 
disorder may be associated with neuronal death through glutamate receptors [112].  
Since Fe levels are increased in PD, it can enhance neuronal death through oxidative 
stress, induce lipid peroxidation and increase ROS production [113, 114]. Fe also 
stimulates the formation of intracellular aggregates of α-synuclein and promotes oxidative 
damage. It is known that autosomal dominant PD is related to mutations in α-synuclein 
that enhance aggregation of the protein; therefore, those individuals with mutations in α-
synuclein could be more susceptible to Fe-induced oxidative damage [57, 115]. 
Several of the regulators of intestinal Fe absorption have also been localized in CNS, 
suggesting a role for these transporters in brain Fe uptake. Among them, DMT1 and 
ferroportin (IREG1) has been identified. In addition, studies report ferroportin in pre-
synaptic vesicles of the striatum, thalamus, brain stem, cerebral cortex and cerebellum, 
suggesting that Fe is transported into vesicles by ferroportin and released as free Fe into 
the synaptic cleft [116]. 
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1.2.2.4.2. COPPER HOMEOSTASIS IN PARKINSON’S DISEASE 
Several studies have shown that Cu may lead to both toxic and protective effects, 
depending on the experimental conditions. Since brain Cu content has been reported to 
be decreased in PD [117]. 
Since its concentration has been found altered in the brain and CSF from PD patients, Cu 
has been implicated in the pathophysiology of the disease [118]. Several studies found 
reduced Cu levels in SNpc and caudate nucleus, but not in cerebellum, globus pallidus, 
putamen or dorsolateral prefrontal cortex from PD patients [91, 119]. In post-mortem 
study, divergent results were found: Cu content was shown to be significantly higher in the 
reticular formation in PD cases [119]. Concerning Cu levels in CSF, while total Cu 
concentration is not changed in PD patients compared to controls, free Cu is increased 
and positively correlated to both disease severity and duration. [120]. It is possible that 
free Cu leads to oxidative stress and neuronal death in PD through Fenton reaction; also, 
free Cu may be increased due to the uncoupling from its binding sites in antioxidant 
proteins (Ceruloplasmin and SOD), leading to oxidative stress.  
The neuroprotective effect of Cu may be related to Fe transport modulation (Figure 6). Cu 
reduces Fe uptake possibly through neuronal DMT1 [121]. Decreased DMT1 expression 
is associated with neuronal survival following Fe overload [122]; thus, an inhibitory effect 
of Cu on Fe uptake is also expected to be neuroprotective. Both oral and 
intracerebroventricular Cu administration are neuroprotective against dopaminergic 
degeneration; oral Cu administration may lead to this effect by decreasing Fe levels since 
Cu competes with Fe for intestinal absorption [121], thus decreasing Fe uptake, and 
consequently, the brain content of this metal. 
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Figure 6: Reciprocal modulation of Fe and Cu and its further association with excitotoxicity in PD. [57]. 
(1) Glutamate increases Fe uptake through a NO-dependent mechanism involving DMT1. (2) Fe may increase 
glutamate release. (3) Excessive glutamate induces excitotoxicity through a NMDA-mediated mechanism. (4) 
Cu can protect neurons against Fe overload by competing for transport through DMT1 and (5) favoring Fe 
efflux through IREG1.  
 
Modulation of Fe transport through ferroportin (IREG-1) may also be involved in the 
neuroprotective effect of Cu since this protein mediates Fe efflux in neurons and 
astrocytes [121, 122]. Increased ferroportin expression is associated with neuronal 
survival after Fe overload [121]. Cu-deficient diets reduce ferroportin expression in the rat 
liver [123], possibly leading to Fe accumulation. In patients with non-alcoholic fatty liver 
disease, low hepatic Cu content is associated with a decreased ferroportin expression, 
contributing to Fe accumulation in those patients [123]. According to those studies, Fe 
accumulation may be the consequence of Cu deficiency.  
 
1.2.3. AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disease with unknown 
pathogenesis, whose rapid progress leads to paralysis and premature death.  
The diagnosis of ALS usually is based on clinical and neurological examination which 
confirms the presence of symptoms characteristic of the combination of upper and lower 
motor neurons degeneration in different anatomical regions of the body (bulbar, cervical, 
thoracic, lumbar regions) [124]. The clinical symptoms of the disorders, such as muscle 
atrophy, weakness or fasciculations, spasticity, speech and swallowing disturbances are 
used for diagnostic procedure [125]. However, appearance of these symptoms reflects a 
far gone neurodegenerative process with significant degeneration of neurons [124].  
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1.2.3.1. EPIDEMIOLOGY  
ALS is one of the most common neurodegenerative disorder, with an incidence of 4-6 per 
100 000 [15]. The onset of disease usually occurs between 50 and 70 years of age but it 
may occur from the teenage years to the late 80’s [124]. 
Most cases of the disease have no genetic linkage (sporadic form) while familial 
amyotrophic lateral sclerosis (FALS) showing dominant autosomal inheritance only 
represents 5-10% of the cases [57]. Mean age of onset of sporadic ALS is 65 years and 
mean age of onset of familial ALS is 46 years [126]. Over 110 FALS-linked mutations 
throughout the Cu,Zn-SOD gene are related to approximately 10-20% of the FALS cases 
[57]. In FALS, Cu,Zn-SOD acquires a toxic function as demonstrated by transgenic 
models showing that mice overexpressing the human mutant enzyme G93A exhibit 
features of ALS [127] while those lacking the enzyme do not develop the disease [57] . 
The incidence of ALS is 1.5 to 2 times higher in men than in women. After 65-70 years of 
age, incidence seems to be equal for both genders [126] . 
1.2.3.2. ETIOLOGY 
Beside the genetic mutations in Cu,Zn-SOD associated to FALS, until today the etiology 
of ALS remains unknown. However, some risk factors have been identified: age at 
menopause (women), diet, family history of ALS or other ND, smoking, previous 
poliomyelitis infection [126]. Most authors support the hypothesis of a complex genetic-
environmental interaction as the causal factor for motor neuron degeneration in ALS. 
 
1.2.3.3. PATHOLOGY 
Clinically, ALS is characterized by the progressive loss of motor neurons of the anterior 
horns in the spinal cord, bulb and cortex [57]. 
The exact molecular pathway causing motor neuron degeneration in ALS is unknown, but 
as with other ND, it is likely to be a complex interplay between multiple pathogenic cellular 
mechanisms which may not be mutually exclusive. These include: excitotoxicity, oxidative 
stress, mitochondrial impaired axonal transport, neurofilament, protein aggregation and 
inflammatory dysfunction [126]. 
Cytoplasmic aggregates such as Bunina bodies and Lewy body-like inclusions have been 
found in motor neurons from both sporadic and familial ALS patients and in transgenic 
mice models of ALS. The association between Cu,Zn-SOD mutations and FALS suggest 
that oxidative injury is involved in this disorder [57].   
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1.2.3.4. TRACE Elements in Amyotrophic Lateral Sclerosis 
1.2.3.4.1. IRON HOMEOSTASIS IN AMYOTROPHIC LATERAL SCLEROSIS 
It has been suggested that Fe accumulation may be due to increased uptake of the metal, 
since lactoferrin [57] is also increased in motoneurons affected by ALS. The increased 
spinal cord Fe levels may be involved in oxidative damage through the Fenton reaction 
[128]. 
The prevalence of hemochromatosis (HFE) gene mutation in ALS patients supports the 
involvement of Fe in this disorder [129]. HFE gene interacts with TfR to sense Fe levels. 
HFE gene mutations are associated with a Cu,Zn-SOD decreased expression, suggesting 
that polymorphisms in ALS are associated an altered Fe homeostasis and, consequently, 
with oxidative damage [130].  
 
1.2.3.4.2. COPPER HOMEOSTASIS IN AMYOTROPHIC LATERAL SCLEROSIS 
Since Cu and Zn are constituents of Cu,Zn-SOD, altered levels of these metals have been 
associated with ALS.  
Altered Zn and Cu levels could be the consequence of structural changes in Cu,Zn-SOD. 
The FALS Cu,Zn-SOD proteins can be divided into two groups according to their metal 
content [131] and the position of the specific mutation: metal content in wild-type-like 
(WTL) mutant SOD is nearly identical to that found in the wild-type protein, whereas 
mutations at the metal-binding region (MBR) or at the electrostatic and Zn loop elements 
[132] lead to a deficiency in Zn and Cu content [131]. WTL Cu,Zn-SOD mutants show high 
reactivity with hydrogen peroxide and produce site-specific oxidative damage to the MBR, 
compromising metal binding, while MBR mutants appear to aggregate with no further 
modification. Hence, the aggregation of both types of mutants may involve metal 
uncoupling [132, 133]. 
Evidence suggests that Cu,Zn-SOD stability is dependent on its metal-binding state. 
Some hypotheses hold that the balance between normal and toxic Cu,Zn-SOD functioning 
depends on Zn binding at the active site of the enzyme (Figure 7); experimental models 
have shown that in the absence of Zn the catalytic reaction of Cu,Zn-SOD runs 
backwards, producing ROS [134]. 
It has been observed that even wild-type human Cu,Zn-SOD, in its metal-free state, may 
form large, stable, soluble, amyloid-like protein oligomers under relatively mild conditions, 
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suggesting that the gain of a toxic Cu,Zn-SOD function in ALS may be related to the 
inability of this protein to achieve or maintain the metallated state [135]. 
The loss of Cu and Zn from Cu,Zn-SOD facilitates the reduction of the intersubunit 
disulfide bound between two residues at the Zn loop, leading to the dissociation of 
subunits and promoting the formation of insoluble aggregates [136]. Cu liberated from Zn 
deficient SOD could potentially initiate apoptosis (Figure 7). 
 
 
 
 
 
 
 
 
Figure 7: The role of SOD metal uncoupling in ALS [57]. 
SOD mutations can be 1) MBR-mutations) or 2) WTL-mutations. MBR-mutant SOD has an altered metal 
content, while WTL-mutant SOD conserves its normal metal content. WTL-mutant SOD is susceptible to 
oxidative damage, compromising metal binding (3). Therefore, both types of mutations can conduce to 
alterations in SOD structure (4), involving protein aggregation (5), gain of toxic function, oxidative damage and 
apoptosis. ROS generated by dysfunctional SOD can potentiate damage to MBR (6). Cu released from SOD 
could be implicated in apoptosis (7). Additionally, Cu and Fe can promote ROS generation through Fenton 
reaction (8). 
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1.3. TRACE ELEMENTS ANALYSIS 
As previously referred, TE are present in biologic matrices at so low concentrations (10 
μg/L to 104 μg/L) that they could not be detected at the beginning of the development of 
instrumental methods of analysis. However, the remarkable development of analytical 
technologies observed in last decades made possible a reliable quantification of these 
chemical species and contributed to the current understanding of the importance of trace 
elements in human health and disease. The development of increasingly sensitive 
analytical methods based on atomic spectrometry has had a major influence on the 
establishment of reference intervals for both essential and toxic elements in human 
populations.  
One of the first important contributions of atomic spectrometry to clinical chemistry was 
the introduction of the flame photometer, based on atomic emission spectrometry, which 
significantly improved sodium and potassium determination [135]. Later, the development 
of atomic absorption spectrometry with flame atomization allowed faster determinations of 
several important metals (e.g., Ca, Mg, Fe, Cu, Zn), with greater accuracy and precision, 
in small sample volumes. However, the range of analyzable metals was reduced due to its 
poor sensitivity (high detection limits). This limitation was overtaken in the 1970s with the 
introduction of the graphite furnace as atomization system, which greatly improves the 
efficiency of the atomization process [136]. The development of absorption 
spectrophotometry with graphite furnace (or electrothermal) atomization allowed to 
decrease by about 10 to 100 times the limits of detection for most metallic elements, 
making possible its quantification at the parts per billion (ppb) level [137] . 
 
1.3.1. ATOMIC ABSORPTION SPECTROMETRY 
In flame atomic absorption spectrometry (FAAS), an air/acetylene or a nitrous 
oxide/acetylene flame is used to evaporate the solvent and dissociate the sample into its 
component atoms. When light from a hollow cathode lamp (characteristic of the element 
to be determined) passes through the cloud of atoms, the atoms of interest absorb the 
light from the lamp.  
Each element absorbs its own characteristic wavelength of light, but a monochromator is 
needed to isolate the particular wavelength of interest from other wavelengths emitted at 
the flame.  The detector is a photomultiplier tube which converts the stream of photons 
into an amplified electrical signal which can be easily measured and used to calculate the 
element concentration in the original sample (solution). The use of a flame limits the 
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excitation temperature to a maximum of approximately 2600 °C (with the N2O/acetylene 
flame) with detection limits in the sub-ppm range [138]. 
 
 
 
 
 
 
 
 
 
Figure 8: Diagram of a flame atomic absorption spectrometer [139]. 
 
Graphite furnace atomic absorption spectrometry (GFAAS) is essentially similar to FAAS, 
however the flame is replaced by a small, electrothermally heated graphite tube, which 
reaches temperatures up to 3000°C to generate the cloud of atoms. The higher atom 
density and longer residence time of the atoms in the tube when compared with the flame 
improve detection limits by a factor of up to 1000x, which decrease down to the sub-ppb 
range [138].  
The heating program in GFAAS comprises four main steps: 1) drying (solvent 
evaporation), performed at temperatures around 100 ºC–120 ºC; 2) pyrolysis, performed 
at about 1000 ºC, which volatilizes the organic and several inorganic matrix compounds 
(but not the analyte); 3) atomization (ca. 2000 ºC), which leads to the production of free 
gaseous atoms of the analyte of interest, in the ground state, so that the light absorption 
by the cloud of atoms can be measured; and cleaning, at high temperatures (2500 ºC), to 
remove all the residues from the graphite tube. 
GFAAS is sensible to matrix interferences, i.e., interferences caused by matrix 
components that inhibit formation of free analyte atoms during the atomization step. This 
problem can be minimized by using chemical “matrix modifiers”, which either stabilize the 
analyte or react with the interfering compounds, leaving the analyte free for quantification.  
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1.3.2. INDUCTIVELY COUPLED PLASMA – MASS SPECTROMETRY 
Inductively Coupled Plasma – Mass Spectrometry (ICP-MS) is a multi-element analytical 
technique that uses a plasma source to dissociate the sample into its constituent atoms. 
Due to the very high temperature of the plasma (6000-10,000 ºC), a significant fraction of 
the atoms are converted into monovalent positive ions. These ions are then separated 
and detected.  
The sample (solution) is introduced into the plasma as an aerosol, by aspirating it through 
a nebulizer. The larger droplets are removed and the remaining reaches the plasma 
(produced at the ICP torch). Here they are completely desolvated and the elements 
present in the sample are converted first into gaseous atoms and then, by losing and 
electron, ionized to monovalent cations. These positive monovalent ions are then 
forwarded to the mass spectrometer via the interface cones, where they are separated by 
their mass-to-charge ratio. In the most common instruments this separation is made with a 
quadrupole (see Fig. 9) [138]. The high number of ions produced, combined with the very 
low background signal, provides the best detection limits available for most elements, 
typically in the parts-per-trillion range.  
 
 
 
Figure 9: Diagram of ICP-MS instruments [140]. 
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However, ICP-MS is not free of limitations. In clinical samples (blood, serum, urine), the 
high concentration of organic and inorganic constituents often results in matrix 
interferences and/or spectral interferences from polyatomic ions. Moreover, the biological 
matrix can clog the nebulizer and the interface cones during long analytical runs. A 
combination of sample dilution, specialized nebulizers and low aspiration flow rates can 
generally reduce clogging of the nebulizer and matrix deposition on the plasma torch and 
sampler/skimmer cones [136]. 
Today, because of its much lower acquisition and operation costs, GFAAS continues to be 
the technique of choice for single trace element analysis [136]. For multielement analysis 
ICP-MS is the most suitable technique because of its rapidity, low detection limits and low 
sample volume required for analysis. 
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II. OBJECTIVES 
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OBJECTIVES 
For a better understanding of the disease-related changes of TE levels in human brain 
and their potential role in neurodegenerative processes, a previous knowledge of their 
physiological (normal) distribution, i.e., their distribution within the brain of healthy subjects 
is essential. 
 However, most of the current information about the relationship between TE and human 
brain functioning is an extrapolation based on animal studies or relies on determinations in 
cerebrospinal fluid and blood.  
On the other hand, it is well known that ND are strongly age-related and there is a specific 
region of the CNS that seems to be particularly affected in each disease 
In this context, the main objectives of our research work were to study, directly in human 
brain samples: 
1) the regional anatomic differences of TE levels within the brain; 
2) the changes on TE levels in relation to age; and 
3) the differences in TE levels between individuals with and without evidence of ND.  
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III. EXPERIMENTAL 
RESEARCH 
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EXPERIMENTAL RESEARCH 
3.1. MATERIAL AND METHODS  
3.1.1. LABORATORY WARE 
Glass and metal materials were avoided in order to reduce the risk of contamination. 
Whenever possible, polypropylene made laboratory ware (pipette tips, volumetric flasks, 
tubes, autosampler cups) was used. 
All material was previously washed with 10% (v/v) HNO3 and rinsed with ultrapure water 
(resistivity > 18.2 MΩ cm at 25 °C) obtained by de-ionization with mixed bed ion-exchange 
resins and further purification in a Milli-Q RG water-purification system (Millipore, Italy). 
3.1.2. SUBJECTS 
This study was conducted in brain samples from individuals (n=44) submitted to medico-
legal autopsy exam at Instituto Nacional de Medicina Legal e Ciências Forenses, I.P. – 
Delegação do Norte (INMLCF, I.P.) during first semester of 2012. 
Brain samples were collected from individuals submitted to medico-legal autopsy by the 
cooperating forensic pathologists at INMLCF, I.P. Only individuals with a post-mortem 
interval not superior to 72 hours were considered. In order to fulfill all current legal 
regulations regarding human tissue collection for scientific research purposes, it was 
assured that the name of the individual was not in Registo Nacional de Não Dadores 
(RENNDA) database. 
Two groups of individuals were studied:  
Group A – “Normal” individuals. Clinical criteria were used for case selection. This was 
based on the absence of neurodegenerative, neurological or psychiatric disorders history 
and/or injuries involving CNS before death and macroscopically normal tissues.  
Individuals from this group were divided in the following age sub-groups: 20-30 (n = 2), 50-
60 (n = 10); 60-70 (n = 10); 70-80 (n = 10); 80-90 (n = 9) and >90 (n = 3) years old.  
Group B – Individuals with evidence of AD (n = 2), PD (n = 1) and ALS (n = 1). 
  
39 
 
Clinical inclusion criteria were defined and case selection was an absence of 
neurodegenerative, neurological or psychiatric disorders history and/or injuries involving 
the central nervous system before death and macroscopically normal tissues. Medical 
status was evaluated on the examination of medical files and the standard questionnaires 
to relatives. Individuals with autopsy findings involving brain hemorrhage (e.g. 
hemorrhagic cerebrovascular accident, head trauma, brain aneurysm rupture) were not 
included in this study. 
3.1.3. SAMPLE COLLECTION 
After removal of the brain from the cranium, the excess of blood was cleansed with 
ultrapure water. Meninges were removed with plastic tweezers and the brain was washed 
again to minimize contamination from blood or cerebrospinal fluid. 
Since there are studies showing no statistical significant differences between brain 
hemispheres [141], the right one was sampled for systematic reasons. (Exceptionally, due 
to non-recent stroke areas on right hemisphere, the left one was sampled in some 
subjects, as described in Attachment 1). 
Using a long-bladed knife, a single horizontal cut was made through the midbrain at the 
level of the superior colliculus to the origin of the third cranial nerve, separating the 
brainstem and cerebellum from the cerebral hemispheres. The cerebellar hemispheres 
were separated from the brainstem by cutting through the superior, middle and inferior 
cerebellar peduncles, and sliced in the coronal plane. Starting at the frontal pole, the 
hemispheres were sectioned at 1 cm intervals in the coronal plane.  
As suggested by Paine and Lowe [68], samples (approximately 1 cm3) were collected  at 
the following brain areas (Figure 10): (1) frontal cortex; (2) (A) superior and (B) middle 
temporal gyri; (3) the basal ganglia including (A) caudate nucleus, (B) putamen and (C) 
globus pallidus; (4) cingulated gyrus; (5) hippocampus; (6) inferior parietal lobule; (7) 
visual cortex of the occipital lobe; (8) midbrain, including the SN to the level of the third 
nerve; (9) pons – locus coeruleus; (10) medulla and (11) cerebellum – dentate nucleus.  
Samples were collected with plastic knives and stored in polypropylene tubes. After 
transport to laboratory in refrigerated conditions, the samples were stored at -4 ºC until 
analysis.  
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Note: To reduce the risk of contamination, all stainless steel material (long-bladed knife 
and scalpel) used by INMLCF cooperating forensic pathologists and all the material that 
contacted with the sample during collection procedure (teflon board, plastic knives, 
tweezers, polypropylene tubes) was previously decontaminated by immersion during 24 
hours on 10% (v/v) HNO3 solution followed by thorough rinsing with ultrapure water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: The suggested regions to be sampled when a neurodegenerative disease is suspected: 1 – frontal 
cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, (B) putamen 
and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – visual cortex of 
the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – pons (locus 
coeruleus); 10 – medulla; and 11 – cerebellum (dentate nucleus) [68].  
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3.1.4. SAMPLE PREPARATION 
Before analysis, brain samples were washed several times with ultrapure water and 
placed in an incubator, at 110 ºC, until constant weight (approximately 24 hours). Between 
100 and 500 mg of dried tissue was weighted in the Teflon microwave oven digestion 
vessels previously washed with ultrapure water. Samples were digested using 2.5 mL of 
concentrated (≥ 65%) HNO3 (TraceSELECT
® Ultra, Sigma-Aldrich, France) and 1.0 mL of 
concentrated (≥ 30%) H2O2 (TraceSELECT
® Ultra, Sigma-Aldrich) in the closed vessels of 
a Milestone MLS-1200 Mega microwave oven equipped with an HPR-1000/10 S rotor 
(Milestone, Italy). The microwave oven program is described in Table 2.   
 
Table 2: Microwave oven program for samples acid digestion. 
 
 
 
 
 
 
After cooling, the vessels content was transferred to decontaminated polypropylene tubes 
and diluted to 50 mL with ultrapure water. All solutions were stored at 4 °C until analysis. 
 
3.1.5. SAMPLE ANALYSIS 
3.1.5.1. FE DETERMINATION 
Fe determination was performed using a PerkinElmer® (Überlingen, Germany) 4100 ZL 
atomic absorption spectrometer equipped with longitudinal Zeeman background 
correction, a transversely heated graphite atomizer (THGA) (end-capped graphite tubes 
with integrated L'vov platform, PerkinElmer Part.No. B3 000653, were used) and an AS-70 
autosampler. An Intensitron™ hollow cathode lamp (PerkinElmer, Norwalk, CT, USA) was 
used as light source (λ = 248,3 nm). High purity (99.9999%) argon (Gasin, Matosinhos, 
Portugal) was used as internal gas. A commercial magnesium nitrate solution (Fluka, 
Step 
Power 
(W) 
Time 
(min.) 
1 250 1 
2 0 2 
3 250 5 
4 400 5 
5 600 5 
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Switzland) was used to prepare the matrix modifier solution (5 µL = 15 µg Mg). 
Instrumental conditions and graphite furnace program used are described in Table 3. 
 
Table 3: Instrumental conditions and graphite furnace program for Fe determination. 
Instrumental parameter 
Wavelength (nm) 
Hollow cathode lamp current (mA) 
Slit with (nm) 
Inert gas 
Flow rate (ml min-1) 
Background correction 
Sample injection volume (μL) 
Matrix modifier injection volume (μL) 
Injection temperature (ºC) 
Pipette speed (%) 
Measurement mode 
Integration time (seconds) 
Baseline Offset Correction (BOC) time (seconds) 
248,3 
30 
0,2 
Argon 
250 (“0” at atomization step) 
Longitudinal Zeeman-effect 
15 
5  
20 
40 
Integrated absorbance (As) 
5 
2 
  
Graphite furnace program 
Step Temperature (ºC) Ramp time (s) Hold time (s) 
Dry 110 1 30 
Dry 130 15 30 
Pyrolysis 1400 10 20 
Atomization 2100 0 5 
Cleaning 2450 1 3 
 
Samples were diluted (100x) with acidified (0.2% v/v HNO3) ultra-pure water before 
injection into the graphite tube. Standard solutions were also prepared by diluting a 
commercial multi-element aqueous solution (PerkinElmer Pure GFAAS mixed standard 
Lot #2-232YP) with acidified 0.2% v/v HNO3. ultra-pure water. Calibration curve was 
obtained with six standard solutions of Fe concentrations equally spaced within the 
calibration range (10-60 μg/L). 
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The limit of detection and quantification were calculated as the concentration 
corresponding to 3 and 10 standard deviations of 10 repeated determinations of the blank, 
respectively. Expressed as μg/L in real samples, the typical Fe detection / quantification 
limits achieved were 1.0 and 3.4, respectively. 
 
3.1.5.2. CU, MN AND ZN DETERMINATION 
Cu, Zn and Mn determination was performed using a VG Elemental (Winsford, UK), 
PlasmaQuad 3 ICP-MS instrument, equipped with a Meinhard® type A pneumatic 
concentric nebulizer, a quartz water-cooled impact-bead spray chamber, a standard 
quartz tube torch and nickel sample and skimmer cones. Both the spray chamber and 
sampling interface were cooled to 12 ºC by circulating water. High purity (99.9999%) 
argon (Gasin) was used as nebulizer and plasma gas. For sample introduction, a Gilson 
(Villiers le Bel, France) model M312 peristaltic pump was used. A 2% (v/v) HNO3 solution 
was used in the washing steps. The main operating conditions for the ICP-MS 
determinations are summarized in Table 4.  
The elemental isotopes (m/z ratios) 55Mn, 65Cu and 66Zn (as analytical masses) and 
45Sc, 89Y, 115In, 159Tb and 209Bi (as internal standards) were monitored. The limit of 
detection and quantification were calculated as the concentration corresponding to 3 and 
10 standard deviations of 10 repeated determinations of the blank, respectively. 
Expressed as μg/L in real samples, the typical detection limits achieved in routine 
operation during the samples analysis were: 0.2 (Mn); 0.4 (Cu); 2.9 (Zn). Quantification 
limits achieved were: 0.7 (Mn); 1.3 (Cu); 9.5 (Zn) respectively. 
A 10 μg/L tuning solution was prepared by dilution of a commercial multi-element aqueous 
solution (AccuTrace™, ICP-MS 200.8-TUN-1; AccuStandards Inc, New Haven, CT, USA). 
The instrument was daily tuned for maximum signal sensitivity and stability using 115In as 
the target isotope. 
Internal standard (Sc, Y, In, Tb and Bi) solution was prepared by dilution of a commercial 
solution (AccuTrace™ Reference Standard, ICP-MS 200.8-IS-1; AccuStandard Inc.). It 
was added to the samples and standards solutions in order to obtain a 10 μg/L final 
concentration. 
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Table 4: Main instrumental and operating conditions for ICP-MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ICP-MS calibrating solutions were prepared by dilution of a commercial multi-element 
aqueous solution (AccuTrace™ Reference Standard, ICP-MS 200.8-CAL1R-1; 
AccuStandards material, S.L., Madrid. Spain). Calibration curve was obtained with six 
solutions of element concentrations within the 1-200 μg/L range.  
All the solutions were prepared with 2% (v/v) HNO3. 
 
3.1.6. QUALITY CONTROL 
Since brain tissue is not available as certified reference materials for, DOLT-4 Dogfish 
liver and DORM-3 Fish Protein Certified Reference Materials for Trace metals (National 
Research Council Canada, Canada) and independent standard solutions were used to 
validate accuracy. CRMs were subjected to the same sample pre-treatment and employed 
at the same concentration range as the analyte content in the sample.  
For contamination control during microwave-assisted acid digestion, a sample blank was 
performed in each digestion cycle (10 samples). 
Instrument parameter Condition 
Detector 
Detection mode 
Acquisition mode 
Pre-scan 
Sequential 
Pulse counting 
Continuous 
Yes 
Setup of the ICP 
Rf power (W) 
Nebulizer gas flow (L/min) 
Auxiliary gas flow rate (L/min) 
Cool gas flow (L/min) 
 
1350 
0.78 
0.60 
13.0 
Setup for main run 
Acquisition mode 
Sweeps 
Dwell time (ms) 
Channels per mass 
Channel spacing 
Replicates 
 
Peak jumping 
200 
10 
1 
0.02 
2 
45 
 
All the samples, after adequate dilution, were analyzed twice (two determinations in the 
same analytical run). For results with relative standard deviation ≥ 10 % another two 
determinations were performed.  
 
3.1.7. STATISTICAL EVALUATION 
 
Statistical analysis of the data was performed using GraphPad Prism 5 for Windows 
(version 5.04) statistical software (San Diego, California, USA).  
For each brain region, of each age sub-groups, element concentration (μg/g) is expressed 
as the mean ± SD from two determinations of each sample. Descriptive statistical 
parameters (mean, median, standard deviation, minimum and maximum) were calculated 
for each element within each brain region. 
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3.2. RESULTS AND DISCUSSION 
3.2.1. REGION DISTRIBUTION OF TRACE ELEMENTS IN NORMAL HUMAN BRAIN 
It was found that brain distribution of TE is not homogeneous. Independently from age, Fe 
is the most abundant metal, followed by Zn and Cu. Zn higher levels were found in 
hippocampus and middle temporal region; higher levels of the other TE were found in 
basal ganglia. Pons and medulla were the regions with lower levels of the four TE studied. 
To illustrate the regional distribution of TE within brain, the mean [TE] (μg/g) of all adult 
individuals of each brain regions was used. 
 
3.2.1.1. IRON 
During adult life, Fe highest levels were found in (3B) putamen (range: 409 – 1155 μg/g), 
(3C)  globus pallidus (577 – 1062 μg/g) and (3A) caudate nucleus (299 – 743 μg/g), while 
Fe lowest levels were found in (10) medulla (44 – 71 μg/g) and (9) pons (64 – 116 μg/g). 
These data are consistent with previous studies, either in vivo, using magnetic resonance 
imaging techniques [142, 143], and post-mortem studies, using atomic absorption 
spectrometry techniques [144, 145] . 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Normal Fe distribution in different regions of adult human brain. 
The specific distribution of Fe in the basal ganglia, co-localized with dopaminergic 
neurons, suggests a special role for this element. It can be concluded from the Fe 
preferential accumulation in these areas that there are certain metabolic processes 
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requiring great amounts of Fe. Cerebellum is also involved in motor coordination but the 
Fe levels found were not as high as in basal ganglia. The reason for this selective Fe 
distribution in different areas of brain related to motor function is yet unknown [146]. 
Putamen is the motor part of the striatum, whereas the caudate is mainly connected with 
more associative cortical regions, not directly involved in motor control [143].  
 
3.2.1.2. COPPER  
In agreement with previous post-mortem studies [144, 145], Cu highest levels were found 
in (3B) putamen (30 – 34 μg/g), while Cu lowest levels were found in (9) pons (5 – 22 
μg/g) and (10) medulla (8 – 13 μg/g).  
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Normal Cu distribution in different regions of adult human brain.. 
 
As also described in literature [147], Cu brain distribution was found not homogeneous. 
Being a cofactor of numerous enzymes, Cu is essential for normal CNS function. High Cu 
levels in certain regions most likely reflect higher metabolic demands for these areas.   
0 - 4 μg/g 
5 - 9 μg/g 
10 - 14 μg/g 
15 - 19 μg/g 
20 - 24 μg/g 
25 - 29 μg/g 
30 – 34 μg/g  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
2A 
2B 
11 
9 
10 
6 
7 7 
1 
4 
6 
11 
10 
9 
8 
3C 3B 
5 
3A 
Medial view Frontal view 
48 
 
3.2.1.3. MANGANESE 
Among the four TE studied, Mn was the less abundant in human brain, whose levels 
found ranged from 0.8 μg/g in (9) pons and (10) medulla, to 2.8 μg/g in (3B) putamen. Mn 
regional distribution found (Figure 13) is concordant with previous post-mortem studies 
referring (3B) putamen and (3A) caudate nucleus as Mn richer regions [148, 149]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Normal Mn distribution in different regions of adult human brain. 
 
 
 
3.2.1.4. ZINC 
Zn was found to be the second most abundant TE in normal human brain. Highest levels 
were found in (5) hippocampus (66 – 81 μg/g) and (2B) middle temporal (62 – 74 μg/g) 
and lowest levels were found in (9) pons (28 – 37 μg/g), (10) medulla (30 – 44 μg/g) and 
(11) cerebellum (34 – 38 μg/g). The distribution found is concordant with literature data, 
which refers that higher zinc levels are found in forebrain regions, including hippocampus, 
amygdala and neocortex [57].  
Since hippocampus and middle temporal are regions related to memory formation, it is 
suggested that Zn plays a role in memory function. 
7 
 
 
 
 
  
 
 
7 
 
 
 
 
 
 
 
 
 
 
 
1 
2A 
2B 
11 
9 
10 
6 
1 
4 
6 
11 
10 
9 
8 
3B 3A 
3C 
0 – 0.4 μg/g 
0.5 – 0.9 μg/g 
1.0 – 1.4 μg/g 
1.5 – 1.9 μg/g 
2.0 – 2.4 μg/g 
Medial view Frontal view 
49 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Normal Zn distribution in different regions of adult human brain.. 
 
Middle temporal and hippocampus, the regions with higher Zn content, are coincident with 
Fe moderate levels; consequently they are probably involved in different metabolic 
reactions [146].   
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3.2.2. AGE-RELATED CHANGES IN HUMAN BRAIN 
It seems to be a trend to elderly people has high levels of the four TE in specific brain 
regions. However, the difference between age-groups was found not significant due to 
substantial heterogeneity of population.  
In summary, these results corroborate  previous reported data from studies on TE 
deposition in human brain, suggesting that accumulation seems to be related to neuronal 
degeneration proceeding in a retrograde way to neuronal cell death with disease 
progression [150]. However, a causative role cannot be implicated due insufficient 
subjects with neurodegenerative diseases for testing causal relationships. 
 
3.2.2.1. IRON 
 
Figure 14: Fe levels (μg/g) age-related changes in different regions of human brain. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
Post-mortem and in vivo studies have demonstrated that, in normal individuals, Fe  levels 
increase over lifetime in subcortical and some cortical gray matter regions [143, 151]. In 
addition, Xu et al. [143] confirmed significant effects of age on brain iron levels. Age-
related increased iron deposition was found in putamen (3B in Figure 15), red nucleus and 
frontal white matter from 22 years to over 70 years, reaching maximal values at about the 
sixth decade. In the globus pallidus (3C), SN and caudate (3A), Fe concentration was 
found unchanged with age. Bilgic et al. [144] also found that elderly people (64 to 86 years 
old) had significantly higher Fe levels in striatal regions of the putamen (3B), caudate 
nucleus (3A), globus pallidus and SN than younger group (21 to 29 years old).  
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Motor disturbances in elderly people can be related with this age-related increasing in Fe 
levels, since it induces free toxic radical production, which leads to tissue oxidative stress 
and neuronal cell death. 
 
3.2.2.2. COPPER 
According to Figure 16, no significant correlation between Cu levels and age seems to 
exist, except for cerebellum (11), where Cu levels seems to be negative correlated with 
age. However, due to high variability between individuals, differences are not significant. 
 
Figure 15: Cu levels (μg/g) age-related changes in different regions of human brain. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
3.2.2.3. MANGANESE 
Mn distribution in the brain varies during development and aging and its alteration might 
be associated with brain maturation and/or functions. Data from literature repot high Mn 
levels in globus pallidus, putamen and caudate [148].  
Our data regarding a Mn distribution (Figure 17) shows a trend for accumulation in brain 
during lifetime in putamen (3B) and globus pallidus (3C). In the other regions Mn levels 
remain quite constant. 
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Figure 16: Mn levels (μg/g) age-related changes in different regions of human brain. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
3.2.2.4. ZINC 
Zn showed to increase with age in middle temporal (2B), hippocampus (5), cingulated 
gyrus (4) and inferior parietal (6) (Figure 18). In the other regions it remains quite 
unchanged.   
 
Figure 17: Zn levels (μg/g) age-related changes in different regions of human brain. 
 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
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Discrepant data can be found in literature. Deibel et al. [152] reported that brain Zn 
remains relatively constant throughout adult life but Panayi et al. [153] found positive 
correlations with age for subjects older than 65 years. 
3.2.3. DISEASE-RELATED CHANGES IN HUMAN BRAIN  
3.2.3.1. ALZHEIMER’S DISEASE 
When compared with non-diseased people of the same age sub-group, TE levels from 
individuals affected by Alzheimer’s disease (n=2) were found significantly altered in 
regions mainly related to memory and learning. 
Although the regions are coincident in the two individuals, the values found were not 
concordant. Explanation for divergent findings could be related to different stages of 
neurodegeneration at the time of death and/or with involvement of other factors 
contributing to the pathology of the disease.  
 
3.2.3.1.1. IRON 
In one AD patient, 73 years old, a statistical significant increase of Fe levels was found in 
several brain regions: 1.9x in caudate, 1.4x in globus pallidus, 2.1x in hippocampus. 
Decreased Fe levels were found in frontal cortex (0.6x) and medulla (0.8x) (Figure 19). 
 
 
 
 
 
 
 
Figure 18: Fe levels (μg/g) in different brain regions of Alzheimer’s disease patients and age-matched control. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
54 
 
In the other patient, it was found a significant increase in Fe levels: around 1.3x in 
superior temporal, 1.7x in caudate, 1.3x in putamen, 1.3x in hippocampus, 1.7x in occipital 
cortex, 1,8x in midbrain and 2.8x in medulla (Figure 19). 
According to Andrási et al. [146], significant differences were expected for Fe in putamen 
(3B), caudate nucleus (3A) and occipital cortex (7), with Fe levels higher in the AD group, 
but not in other studied brain regions (frontal and parietal cortex, globus pallidus and 
thalamus). 
One remarkable features of AD is the accumulation of Fe in neurofibrillary tangles and 
senile plagues that was found to be specifically associated with the lesions of AD [146]. 
Excess Fe could mobilize metals (e.g., Al and Mn) and thus increases the chance of 
neurological damage of CNS, such as dementia [57]. 
 
3.2.3.1.2. COPPER 
It seems that Cu distribution is particularly affected in AD patients’ brain. Significant 
changes in almost all sampled regions were found for both AD cases.  
In one AD patient, 73 years old, significant lower Cu levels were found in all regions: 
frontal cortex (0.6x), superior temporal (0.7x), middle temporal (0.6x), putamen (0.7x), 
cingulated gyrus (0.4x), hippocampus (0.6x), parietal inferior (0.7x), occipital cortex (0.7x), 
midbrain (0.6x) and medulla (0.6x) (Figure 20). 
In the other AD patient, however, a significant increase of Cu levels was found in all brain 
regions: frontal cortex (2.0x, p<0.0001), superior temporal (1.6x), middle temporal (1.4x), 
caudate (1.9x), putamen (1.5x), caudate (1.5x), cingulated gyrus (1.5x), hippocampus 
(2.0x), parietal inferior (2.1x), occipital cortex (1.8x), midbrain (1.8x), pons (1.9x), medulla 
(2.5x) and cerebellum (1.3x) (Figure 20). 
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Figure 19: Cu levels (μg/g) in different brain regions of Alzheimer’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
Previous studies on the role of copper in AD development and progression are also 
inconsistent and occasionally contradictory. Deibel et al. [152] showed a significant 
decrease of Cu in hippocampus. Platin et al. [154] also found significantly decrease of Cu 
levels in frontal, temporal, parietal and occipital lobes in AD compared with controls.  
The involvement of Cu in AD development is complex and multilayered. Extracellular 
amyloid plaques, one of the two key pathologies present in AD brains, are enriched with 
Cu [155]. However, the brain tissues of AD patients are paradoxically Cu-deficient [124–
127]. Cu complexes with Aβ, which is linked to ROS-related neurotoxicity, Aβ aggregation 
and formation of amyloid plaques. Copper–Tau interaction has been also hypothesized to 
induce the development of intracellular NFTs, the other characteristic hall-mark of AD [57].  
 
3.2.3.1.3. MANGANESE 
In one AD patient Mn levels were found to be significantly reduced in frontal cortex (0.7x), 
superior temporal (0.8x), caudate (0.8x) and hippocampus (0.6x). 
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In other hand, in the older AD patient higher Mn levels were found in frontal cortex (1.2x), 
caudate (1.6x), putamen (1.6x), hippocampus (1.3x), inferior parietal (1.7x), occipital 
cortex (1.6x), midbrain (2.0x), pons (1.7x), and medulla (1.8x) (Figure 21). 
 
 
Figure 20: Mn levels (μg/g) in different brain regions of Alzheimer’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
Until recently, the majority of the studies examining the neurological consequences of 
chronic Mn exposure were focused on Mn effects on basal ganglia, due to its effects on 
motor function [156]. Last decade, a number of human studies have demonstrated Mn-
induced deficits in attention and cognitive impairment that may persist long after exposure 
[157, 158]. It has been suggested that Mn effects on the frontal cortex and subcortical 
structures may be associated with these cognitive and executive function deficits [159], 
inducing diffuse amyloid-beta plaques in frontal cortex, potentially supporting a link 
between advanced-stage manganism and dementia. 
In accordance with the above cited study, we found significantly increased Mn levels in 
cortical regions, which may be a contributing factor for AD pathogenesis. But, since there 
is a lack of evidence linking Mn with AD, further studies are needed.  
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3.2.3.1.4. ZINC 
As already described for other TE, changes found in AD patients were not concordant: in 
one patient Zn levels were found to be significantly increased in all brain regions, but not 
on the other one.   
 
Figure 21: Zn levels (μg/g) in different brain regions of Alzheimer’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
Regarding Zn levels and AD, there are contradictory reports in literature. Several authors 
report increased levels of Zn in AD subjects compared to normal groups: Deibel et al. 
[154] found increased levels in hippocampus; Cornett et al. [153] found Zn increased 
concentrations in frontal, temporal, parietal lobes, hippocampus and cerebellum. 
The consequences of high levels of Zn in neurodegenerative diseases such as AD have 
been discussed. Bush et al.[160] showed that Aβ specifically bind to Zn and, at high 
concentrations, this metal accelerates protein aggregation suggesting a role in the 
pathogenesis in AD. 
Contrarily, several authors reported decreased levels of Zn in AD subjects in the basal 
ganglia, central cortex, putamen and hippocampus [144, 153]. There is lesser information 
regarding the role of low levels of Zn in AD. Some authors suggest that amyloid 
accumulation allows metals to enter the brain via disrupted BBB, but that is a 
displacement and loss of Zn, which leads to neurofibrillary tangles and dementia [153]. 
Lovell et al.[75] refer low Zn levels as protective against Aβ toxicity due to the 
enhancement of Na+/K+ ATPase activity, which prevents consequences of Aβ 
aggregation such as the disruption of calcium homeostasis and cell death. 
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Furthermore, no significant differences were found for Zn levels in cortex, temporal, 
parietal and frontal areas [153].  
The heterogeneity of these results could be due to different stage of neurodegeneration at 
the time of death, insufficient number of subjects, dietary, geographical and environmental 
variations between subjects, differences in tissue sampling, handling protocols and 
different sensibility methods.   
3.2.3.2. PARKINSON’S DISEASE 
3.2.3.2.1. IRON 
In the PD patient, significantly higher Fe levels were in globus pallidus (2,3x), cingulated 
gyrus (1,5x) and hippocampus (1,3x). In inferior parietal cortex it was observed a 46% 
reduction of Fe levels. 
In normal brain, Fe was found predominantly in the extrapyramidal system, in particular 
the globus pallidus, SN and putamen. Fe deposition normally increases with age but the 
accumulation observed in PD patient exceeds the increasing found in normal elderly 
individuals in basal ganglia (3 A-C; Figure 23). Previous studies also report similar data: 
increased levels on SN and globus pallidus [103, 150, 151]. Moreover, Fe deposits seems 
to be correlated with the severity of the disease [103, 152, 153]. 
 
Figure 22: Fe levels (μg/g) in different brain regions of Parkinson’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
The most characteristic hallmark in PD is the loss of dopaminergic neurons in the pars 
compacta region of the SN. SN is the source of the striatal input of the neurotransmitter 
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dopamine, which plays an important role in basal ganglia function [161]. Injury of 
dopaminergic projections from SN to the caudate nucleus and putamen is the cause of the 
main motor symptoms on PD patients such as rest tremor, rigidity, bradykinesia and 
postural instability.  
 
3.2.3.2.2. COPPER 
Reduced Cu levels in PD brain were found in some regions, namely putamen (0.6x), 
hippocampus (0.7x), inferior parietal (0.7x) and pons (0.2x) (Figure 24). In literature, 
contradictory results can be found: several studies found decreased total Cu levels in 
SNpc and caudate nucleus, but not in cerebellum, globus pallidus or putamen of PD 
brains [91, 119], but increased levels are also reported [119]. 
 
 
 
Figure 23: Cu levels (μg/g) in different brain regions of Parkinson’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
Some authors suggest that Cu may lead to both toxic and protective effects depending on 
the experimental conditions. However, since brain Cu levels have been reported to be 
decreased in PD [117], the toxic effects that occur at high concentrations are not likely to 
be involved in the pathophysiology of the disorder. Due to non-concordant results 
available in literature, further research is needed to clarify the dual role of Cu in PD. 
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3.2.3.2.3. MANGANESE 
Mn levels was found significantly increased in particular brain areas of the PD patient, 
namely in putamen (3.3x), cingulated gyrus (1.6x), hippocampus (1.4x), inferior parietal 
(1.5x), occipital cortex (1.4x), midbrain (1.5x) and medulla (2.1x). 
Manganese toxicity is clearly associated with damage of basal ganglia structures, as 
observed in animal and human studies [162]. The exact mechanism of Mn neurotoxicity 
and the reason for the globus pallidus selective vulnerability is still unknown. It is thought 
that its toxicity is mediated by excessive oxidative stress, enhanced free radical formation 
and decreased glutathione levels, leading to cell death [162].  
 
Figure 24: Mn levels (μg/g) in different brain regions of Parkinson’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
Various mechanisms mediated by Mn could converge on α-synuclein in vivo, potentially 
connecting Mn to PD [163]. Mn can directly increase fibril formation and to act jointly with 
α-synuclein in neuronal  cell  death inducing [164]. Overexpression of α-synuclein in 
human cells seems to facilitate Mn-induced neurotoxicity and possibly plays a role in 
dopaminergic cell death [165].   
3.2.3.2.4. ZINC 
In PD-affected brain, Zn levels were found increased in (5) hippocampus (1.2x), but they 
were decreased in (1) frontal cortex (0.5x), and (3A) caudate (0.9x).  
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Figure 25: Zn levels (μg/g) in different brain regions of Parkinson’s disease patients and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
Previous studies found significantly decreased levels of Zn in putamen, caudate nucleus, 
globus pallidus and SN [117], suggesting that a Zn disrupted homeostasis could be also 
involved in PD.  
 
3.2.3.3. AMYOTROPHIC LATERAL SCLEROSIS 
3.2.3.3.1. IRON 
Fe levels were found decreased in some brain regions of a ALS patient, namely: frontal 
cortex (-22%), superior temporal (-41%), middle temporal (-23%), caudate (-58%), globus 
pallidus (-42%), inferior parietal (-32%) and pons (-57%).  
Increased spinal cord Fe levels were reported in ALS but there is a lack of studies in brain 
tissue [166]. Although lower Fe levels were found in regions related to motor functions, 
further studies are needed in order to elucidate Fe involvement in this disease. 
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Figure 26: Fe levels (μg/g) in different brain regions of amyotrophic lateral sclerosis patient and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
 
3.2.3.3.2. COPPER 
Compared with age-matched control, Cu levels were not found significantly altered in ALS 
brain, with the exception of cerebellum, where a 1.4x increase was observed. These data 
suggest that, in this subject, Cu homeostasis was not altered and it was not a major 
contributing factor for ALS pathology.  
 
 
 
 
Figure 27: Cu levels (μg/g) in different brain regions of amyotrophic lateral sclerosis patient and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
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3.2.3.3.3. MANGANESE 
Mn was found reduced in superior temporal (0.6x), caudate (0.7x) and inferior parietal 
(0.4x). In hippocampus and midbrain, a slight increase was observed (1.2x and 1.1x, 
respectively).  
 
Figure 28: Mn levels (μg/g) in different brain regions of amyotrophic lateral sclerosis patient and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
Mn overload has been implicated in ALS. There is documented evidence that Mn smelters 
and welders who developed occupational manganism also showed some neurological  
signs of motor neuron disease and bulbar ALS [31]. In addition, a significant percentage  
of  ALS  patients  show  neuroradiological  signs  compatible  with  Mn overload  (T1-
weighted hyperintensity) in areas related to the motor system [167], but  to  date no  
studies  have  directly  quantified  Mn  levels  in  these  regions in  ALS  patients. Further, 
Mn overload induces apoptosis, which contributes to motor neuron disease [31]. 
Until today, there is not a definitive proof linking Mn to ALS, these observations 
collectively indicate that in certain conditions the metal can cause or trigger motor neuron  
disease in some individuals [31] . 
In the ALS patient studied, Mn levels were not significantly different from age-matched 
controls. Brain regions linked to motor control (putamen, globus pallidus or caudate 
nucleus) showed no changed levels of Mn, but it was noticed a slightly increase in 
hippocampus and midbrain.  
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3.2.3.3.4. ZINC 
When compared with age-matched control, Zn levels were found to be decreased in 
superior temporal (0.7x), middle temporal (0.7x), caudate (0.8x), globus pallidus (0.8x) 
and inferior parietal (0.7x). Zn levels in midbrain and cerebellum were found to be 
increased 1.3x and 1.2x, respectively.  
Since there is an association between Cu,Zn-SOD mutations and ALS, altered levels of 
those metals have been associated with ALS pathology, suggesting that oxidative injury is 
involved in this disorder [57]. As previously described, TE altered levels in CSF and serum 
are reported but there is a lack of data of direct determinations in brain tissue [57].  
 
Figure 29: Zn levels (μg/g) in different brain regions of amyotrophic lateral sclerosis patient and age-matched 
controls. 
1 – frontal cortex; 2 – (A) superior and (B) middle temporal gyri; 3 – basal ganglia, including the (A) caudate, 
(B) putamen and (C) globus pallidus; 4 – cingulated gyrus; 5 – hippocampus; 6 – inferior parietal lobule; 7 – 
visual cortex of the occipital lobe; 8 – midbrain, including the substantia nigra at the level of the third nerve; 9 – 
pons 10 – medulla; and 11 – cerebellum . 
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CONCLUSIONS AND FUTURE RESEARCH 
Since no updated and comprehensive data about trace elements in human brain are 
available, this study may be a relevant scientific contribution for establishing “normal” 
human brain levels, allowing future comparisons of levels found in brains affected by 
neurodegenerative diseases, in an attempt to clarify trace elements role in the disease 
process. 
Data obtained clearly show that there is an inhomogeneous distribution of trace 
elements within the brain tissue. This can be regarded as a proof of an important 
physiologic role of trace elements in brain functioning. 
On the other hand, age-related changes are not so clear. Globally, there is not evident 
any significant increase or decrease. However, in specific regions, significant changes 
were observed, which also supports a role for trace elements in age-related motor and 
cognitive problems.          
Due to the limited number of subjects with ND and the population heterogeneity, the 
presented results should be considered as preliminary. However, they seem to 
corroborate the hypothesis that trace elements play an important role in 
neurodegenerative diseases, since significant differences were observed regarding their 
distribution in specific brain regions. Further investigation of regional distribution of trace 
elements in brain tissue, with particular focus on the correlation with health and disease 
status, in order to understand age- and disease-related motor slowing and other selective 
cognitive decline [142]. 
Given the multifactorial nature of neurodegenerative diseases, it is becoming evident that 
the next generation of therapies must have multiple functions to combat multiple 
mechanisms of disease progression [49]. Since metals have gained increased importance 
regarding a potential involvement in ND, inhibiting metal-promoted damage by use of 
small chelating agents could be a potential strategy for treating diseases associated with 
localized metal accumulation [49]. However, the current understanding of metal 
homeostasis in CNS is still very limited, which difficult the interpretation of the effects of 
manipulating metals within the brain [51]. It is crucial to clarify the mechanisms involved in 
oxidative stress and other factors responsible by neuronal degeneration, since it is 
essential to find new effective therapeutic approaches in order to improve not only the 
effective treatment of neurodegenerative diseases but also to delay their onset.  
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Attachment 1 – Description of analyzed subjects with no 
documented neurodegenerative diseases. 
Age Range Cause of Death Gender Age 
Brain 
Hemisphere 
Post-mortem 
Interval (hours) 
20-30 
Chest trauma by firearm M 20 R 24 
Asphyxia from hanging M 24 R 24 
50-60 
Asphyxia from hanging M 57 R 24 
Burning lesions M 53 R 24 
AMI M 58 R 24 
ANHP M 56 R 24 
AMI M 54 R  
? M 57 R 24 
? M 54 R  
AMI M 55 R 72 
AAA rupture F 54 R 24 
Asphyxia from hanging M 56 R 24 
60-70 
AMI M 68 R 48 
AMI M 60 R 24 
AMI M 60 L
1
 14 
AMI M 66 R 48 
AMI M 63 R 24 
AMI M 68 R 24 
Multiorgan failure F 69 L
1 
24 
AMI M 63 R 72 
? F 60 R  
asphyxia from drowning f 68 L
1 
12 
70-80 
Acute pancreatitis F 76 R 24 
Cardiorespiratory 
insufficiency 
M 75 R 24 
AAA rupture M 71 R 24 
Cardiomyopathy 
ischemic 
F 71 R  
PA rupture M 72 R 48 
Asphyxia from hanging M 72 R 36 
? F 71 R 48 
? F 70 R 20 
? F 73 R 24 
Acute pancreatitis M 78 R 14 
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Age Range Cause of Death Gender Age 
Brain 
Hemisphere 
Post-mortem 
Interval (hours) 
80-90 
 
 
Digestive hemorrhage M 81 R 72 
Pulmonary infection F 84 R 18 
AAA rupture M 84 R 48 
? F 82 R  
? M 80 R 12 
Chest trauma by firearm M 81 R 24 
Asphyxia from hanging M 88 R 24 
 M 84 R  
Asphyxia from hanging F 88 R 24 
≥90 
Pneumonia F 92 R  
Cardiac rupture F 90 L
1
  
Respiratory infection F 102 R  
ANHP: Acute Necrohemorrhagic Pancreatitis; AMI: Acute Myocardial Infarction; AAA: 
aortic abdominal aneurysm; PA: Pulmonary artery; ?: undetermined cause of death; M: 
Male; F: Female; R: Right; L:  Left. 
 
Attachment 2 – Description of analyzed subjects with 
documented neurodegenerative diseases. 
ND Cause of Death Gender Age 
Brain 
Hemisphere 
Post-mortem 
Interval (hours) 
AD 
Pulmonary 
thromboembolism 
F 73 R  
AD 
Consumption 
coagulopathy 
F 85 R  
PD  F 91 R  
ALS Vomit aspiration M 84 R 24 
 
 
 
 
  
                                               
1
 It was sampled the left hemisphere due to non-recent stroke areas on right hemisphere. 
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Attachment 3 – Distribution of Cu (μg/g dry tissue) in different 
regions of healthy human brain. 
Age range 1 2A 2B 3A 3B 3C 4 5 6 7 8 9 10 11 
20-30 
21 32 15 5 119 14 52 10 24 21 21 6 6 32 
19 19 16 18 33 21 17 20 20 18 18 24 5 10 
50-60 
37 28 34 30 35 27 27 34 37 32 39 31 21 29 
40 38 37 52 47 29 46 27 43 40 38 36 9 31 
22 39 16 14 34 15 13 11 40 20 19 4 11 19 
22 23 20 30 30 16 24 16 21 23 20 6 10 23 
15 12 20 11 36 11 19 16 16 16 19 6 4 23 
20 21 35 29 22 36 32 33 13 24 15 30 10 27 
21 21 19 2 27 17 14 18 26 23 31 7 15 27 
31 40 28 71 55 2 1 30 23 27 25 11 15 27 
20 39 17 3 70 45 30 17 30 22 18 11 7 32 
18 17 23 16 42 15 8 17 25 16 22 6 13 18 
60-70 
18 18 18 23 23 18 16 15 18 17 24 23 30 4 
13 14 9 15 65 16 18 9 13 17 18 9 3 23 
20 20 20 21 29 21 18 16 15 22 19 19 6 23 
18 14 16 28 31 17 17 16 25 25 26 29 7 26 
14 14 14 13 21 15 13 12 16 19 24 23 9 23 
20 19 22 15 31 31 22 16 17 17 15 13 7 23 
19 18 23 31 38 24 18 16 18 23 25 17 16 28 
25 21 24 29 34 22 24 17 22 23 22 51 28 6 
27 31 29 33 42 59 13 21 26 29 21 22 10 26 
16 13 30 5 76 14 12 15 26 20 19 6 9 16 
70-80 
7 26 28 34 42 19 26 45 18 29 37 29 48 18 
31 37 38 22 30 26 30 26 31 32 25 19 14 29 
23 15 21 31 33 19 14 12 15 17 14 7 7 12 
19 27 23 26 32 19 27 25 27 26 33 22 20 31 
16 16 18 15 23 18 13 10 22 14 20 12 8 17 
17 18 20 9 22 31 23 10 32 22 24 5 13 21 
17 17 20 4 91 12 52 17 23 19 9 7 8 22 
24 18 15 20 33 41 8 53 8 27 24 8 14 24 
26 16 27 48 31 21 33 18 35 33 24 10 15 33 
17 16 17 22 27 19 2 9 13 15 16 12 21 4 
80-90 
23 22 22 27 47 28 21 16 19 17 26 16 5 64 
19 19 19 21 29 25 18 15 20 22 22 19 15 31 
14 15 18 14 26 14 9 10 10 11 11 4 7 16 
22 21 X 38 34 19 15 15 18 21 27 11 12 23 
19 31 17 8 61 30 19 9 90 23 21 8 10 24 
18 16 28 41 36 22 21 20 79 27 31 7 6 16 
25 25 24 26 33 22 23 18 23 23 23 15 11 28 
9 12 8 8 23 19 7 6 8 9 11 X 2 11 
14 26 18 24 26 14 14 15 17 20 21 7 5 19 
> 90 
21 19 20 32 39 27 20 18 20 23 26 27 6 20 
32 25 29 17 38 17 30 21 29 23 28 20 11 21 
13 17 42 22 37 29 23 18 19 20 19 20 10 15 
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Attachment 4 – Distribution of Fe (μg/g dry tissue) in different 
regions of healthy human brain. 
 
Age range 1 2A 2B 3A 3B 3C 4 5 6 7 8 9 10 11 
20-30 
318 277 231 402 414 884 169 211 251 290 222 80 86 182 
246 188 171 195 404 498 142 184 184 237 259 47 23 114 
50-60 
463 497 478 574 701 1083 329 353 412 431 273 125 68 206 
232 262 316 872 1337 703 1572 252 246 270 312 100 23 155 
336 393 328 242 624 430 264 282 336 391 349 84 76 131 
254 267 247 581 706 419 198 191 261 285 251 75 38 256 
185 217 187 380 447 251 117 154 189 181 169 29 35 156 
207 264 219 609 934 924 185 234 281 220 107 418 49 164 
237 282 295 27 908 460 85 248 271 378 206 83 53 422 
232 293 346 926 835 401 170 261 342 394 290 131 63 306 
248 210 225 621 861 697 180 204 211 288 203 80 20 520 
234 231 257 500 415 402 215 207 242 282 409 74 52 120 
60-70 
330 347 244 908 488 343 187 230 263 300 437 88 43 124 
255 259 246 557 731 1004 206 136 444 340 212 146 13 238 
329 315 367 486 830 1040 208 281 212 322 351 106 59 385 
282 337 232 532 855 440 184 232 304 395 314 95 37 309 
304 211 285 306 839 646 235 277 251 228 278 142 28 450 
315 343 345 278 691 1194 360 368 296 317 360 79 101 457 
279 289 325 962 1973 1350 257 284 372 436 572 151 79 358 
216 273 247 248 858 799 229 213 231 290 311 51 64 150 
211 207 205 396 909 395 262 170 183 152 206 29 60 109 
282 310 267 648 659 382 186 205 270 299 173 89 77 287 
70-80 
245 291 429 763 1042 501 215 196 219 327 367 123 64 188 
314 326 320 199 504 225 312 283 287 279 271 110 53 244 
375 451 389 672 958 724 242 274 395 355 342 112 69 416 
272 295 299 528 845 428 257 292 345 475 326 101 179 425 
308 292 337 334 500 572 291 156 345 604 420 121 89 239 
427 297 235 502 627 281 191 240 287 365 214 70 76 156 
180 193 176 579 1132 789 145 149 198 206 54 11 50 315 
306 263 295 859 328 459 336 250 302 758 293 148 115 345 
333 311 234 537 1108 867 258 259 365 274 219 69 68 409 
389 397 364 1103 1439 1078 218 271 311 314 260 130 55 249 
80-90 
290 257 248 902 2742 1539 224 281 265 289 247 71 18 468 
296 364 316 313 1628 1870 325 332 376 487 481 145 95 410 
293 178 588 825 1460 428 208 337 215 180 237 35 72 406 
192 223 X 787 782 1061 162 222 232 293 492 116 71 192 
209 270 240 1477 1563 745 167 206 230 335 470 94 28 218 
582 165 269 877 1037 1510 384 232 457 443 308 253 17 225 
174 291 202 528 973 818 156 156 189 261 224 89 31 349 
282 327 278 284 1149 1255 231 178 291 312 230 X 23 241 
213 452 235 691 651 331 172 272 339 162 252 129 275 237 
> 90 
428 343 378 646 677 735 221 227 256 328 246 121 63 200 
330 366 303 268 1246 405 292 226 296 423 415 35 0 447 
161 208 465 279 1007 1066 214 228 265 289 152 98 82 215 
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Attachment 5 – Distribution of Mn (μg/g dry tissue) in different 
regions of healthy human brain. 
 
Age range 1 2A 2B 3A 3B 3C 4 5 6 7 8 9 10 11 
20-30 
1,06 0,95 0,92 2,22 1,98 1,62 0,85 1,21 0,87 1,13 1,06 0,67 0,64 0,81 
0,86 0,94 0,96 1,84 2,35 1,57 0,92 1,14 1,02 1,01 1,14 0,85 0,83 0,77 
50-60 
0,99 0,59 1,02 0,92 1,63 1,36 0,76 0,77 0,98 1,02 1,06 0,81 0,72 0,49 
1,15 1,23 0,95 2,63 3,33 3,02 1,55 1,82 1,60 1,53 1,67 1,18 0,32 0,96 
1,12 1,07 1,09 1,71 2,50 1,63 1,04 1,55 1,03 1,29 1,37 0,76 0,98 0,90 
0,99 0,91 0,88 2,28 2,28 1,32 1,00 1,12 0,90 0,91 0,92 0,63 0,68 0,68 
0,96 1,00 0,99 2,39 2,04 1,19 0,91 1,22 0,89 0,93 1,15 0,80 0,57 0,76 
0,81 0,94 0,98 2,10 2,61 1,88 0,92 1,13 0,96 1,04 0,63 1,73 0,80 0,75 
0,67 0,64 0,65 0,04 1,75 0,81 0,19 1,34 1,06 0,84 1,30 0,81 0,76 1,08 
1,07 1,14 1,08 4,04 2,75 1,97 1,07 1,13 1,18 1,04 1,18 1,00 0,83 1,02 
1,04 0,98 1,02 2,49 2,53 1,88 0,99 1,22 0,98 1,38 1,14 0,93 0,98 0,93 
0,94 1,09 0,98 2,10 1,64 1,18 0,92 1,21 0,88 1,02 1,13 0,52 0,65 0,68 
60-70 
0,97 0,92 0,99 2,35 1,83 1,37 1,00 1,53 1,01 1,04 1,27 0,99 1,24 0,45 
0,88 0,88 0,85 1,94 1,81 1,54 0,95 0,53 2,12 0,92 0,85 0,50 0,24 2,07 
0,99 0,97 1,04 1,59 2,27 1,89 0,99 1,24 0,75 1,59 1,08 0,81 0,65 0,79 
0,89 0,54 0,73 8,97 3,24 1,67 3,28 1,17 1,44 1,91 1,27 1,13 0,99 0,78 
0,76 0,73 0,79 0,92 1,40 0,88 0,85 0,75 0,80 1,14 0,97 1,16 0,82 0,57 
0,40 0,37 0,41 0,43 0,68 0,63 0,40 0,40 0,64 0,54 0,51 0,46 0,27 0,49 
1,03 0,91 1,10 2,75 3,20 2,30 1,04 1,20 1,06 1,51 1,41 0,93 0,97 0,99 
1,16 1,02 1,02 2,39 2,69 2,66 1,02 1,36 1,06 1,21 1,19 1,45 1,21 0,52 
1,35 1,79 1,77 3,88 4,53 3,53 3,76 2,23 1,84 2,58 2,69 1,97 1,81 1,80 
0,92 0,94 0,90 2,00 1,84 1,17 0,85 0,94 0,86 1,03 0,98 0,59 0,74 0,84 
70-80 
0,60 1,12 1,16 2,63 3,03 1,47 1,08 2,06 0,74 1,67 1,64 1,42 2,40 0,87 
1,00 1,05 0,99 2,31 0,72 1,46 1,05 1,10 1,03 1,23 0,76 0,72 0,72 0,78 
1,63 0,78 1,60 3,94 3,26 2,27 1,16 1,59 1,24 1,39 0,92 0,68 0,76 0,83 
1,38 1,57 1,44 2,48 2,80 1,30 1,05 1,16 1,15 1,38 1,16 0,85 1,11 0,96 
0,91 0,93 1,02 1,50 1,71 1,36 0,83 0,67 1,24 0,85 0,97 0,70 0,74 0,75 
0,98 0,95 0,91 2,67 2,20 1,64 1,03 1,50 1,23 1,29 1,22 0,66 1,07 0,85 
0,65 1,05 0,69 2,46 2,97 2,55 1,02 1,23 1,00 1,18 0,70 0,70 0,68 1,03 
1,23 1,05 1,14 2,34 1,26 1,58 1,21 1,26 1,10 2,21 1,19 0,80 0,97 0,83 
0,92 0,87 1,05 1,68 2,53 1,42 2,33 1,17 1,02 1,00 0,85 0,59 0,75 0,83 
1,12 1,03 1,15 2,68 3,15 2,87 1,01 1,19 0,95 1,01 0,92 0,83 1,22 0,77 
80-90 
1,08 1,18 1,05 2,38 3,64 3,27 4,04 1,14 0,96 1,06 0,83 0,61 0,38 1,83 
0,94 1,09 0,86 2,61 2,23 2,07 0,69 0,98 1,09 1,23 0,99 0,59 0,81 0,72 
0,91 0,84 0,95 1,76 2,08 0,96 0,86 1,10 0,79 1,00 0,81 0,53 0,65 0,64 
1,12 0,91 X 2,60 2,56 7,67 0,79 1,29 0,82 0,95 0,98 0,73 0,82 0,83 
0,90 0,85 0,95 2,66 2,94 1,40 0,83 1,10 0,89 0,88 0,89 0,57 0,79 0,77 
0,80 0,80 1,61 3,14 4,46 5,17 2,61 1,84 6,93 2,72 2,13 0,69 0,98 1,00 
0,88 1,08 0,90 1,56 2,12 1,29 0,68 0,89 0,67 0,76 0,78 0,62 0,62 0,83 
1,15 1,36 1,12 1,92 3,09 2,79 1,13 1,17 1,12 1,17 1,10 X 0,88 1,18 
0,75 1,41 1,02 2,60 2,31 1,26 1,02 1,21 0,94 1,04 0,99 0,56 0,81 0,82 
> 90 
1,13 0,93 1,26 2,08 2,24 2,79 1,07 1,25 1,03 1,18 1,02 0,97 0,59 0,80 
1,50 1,49 1,36 1,52 3,25 1,97 1,54 1,40 1,22 1,25 1,29 0,93 0,89 1,03 
0,69 0,94 1,98 1,71 2,72 2,23 1,18 1,44 1,08 1,02 1,05 1,12 1,37 1,18 
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Attachment 6 – Distribution of Zn (μg/g dry tissue) in different 
regions of healthy human brain. 
 
Age range 1 2A 2B 3A 3B 3C 4 5 6 7 8 9 10 11 
20-30 
62 60 59 83 62 48 43 69 55 54 38 28 26 39 
53 60 64 39 72 37 43 66 48 43 32 30 34 30 
50-60 
72 57 76 67 63 47 53 81 72 63 44 42 43 32 
51 49 52 72 53 37 69 57 60 54 37 30 11 26 
56 23 63 45 48 35 44 71 43 46 33 26 31 33 
54 61 54 44 49 27 72 78 58 57 34 26 31 25 
53 45 57 53 42 27 53 69 45 49 34 40 23 33 
53 65 75 63 70 53 60 69 58 56 23 51 41 34 
61 56 61 7 54 31 33 86 58 50 51 38 41 46 
72 61 72 73 68 34 59 50 61 65 41 33 34 41 
67 70 65 71 65 54 59 65 56 52 38 35 24 38 
60 61 59 52 47 33 52 79 55 54 34 24 32 32 
60-70 
65 57 67 86 53 38 57 79 60 49 41 38 39 18 
50 59 62 56 47 47 57 26 142 45 26 19 9 87 
63 63 69 46 62 51 55 70 45 47 32 30 59 43 
50 33 49 70 61 43 49 59 82 64 47 40 34 36 
61 53 63 43 55 41 59 57 63 68 56 50 43 47 
67 67 81 46 68 66 63 71 69 55 49 39 41 54 
62 54 75 73 85 59 59 72 68 65 48 42 47 47 
71 55 66 60 61 44 58 65 63 54 40 49 36 20 
60 66 65 53 60 124 20 64 53 59 35 26 24 41 
51 59 59 46 50 37 40 56 51 55 37 26 32 32 
70-80 
29 56 68 72 68 35 67 95 41 96 88 66 69 32 
65 79 78 55 57 58 59 66 61 59 37 33 36 39 
92 51 78 81 68 42 58 64 52 55 27 24 23 27 
55 75 65 59 51 28 70 81 60 57 46 42 56 45 
68 58 77 48 65 41 50 49 77 46 39 32 33 36 
45 44 43 58 44 35 41 69 49 53 33 28 33 32 
29 70 46 56 59 63 56 64 59 54 28 28 30 44 
68 61 69 56 51 41 67 71 60 65 38 31 35 34 
59 51 79 57 75 47 67 87 71 73 34 26 38 41 
72 57 77 71 73 52 54 63 56 43 32 29 43 18 
80-90 
67 66 78 62 94 63 60 65 61 48 36 28 14 76 
69 49 65 77 66 61 53 69 75 55 42 27 36 44 
72 65 86 46 86 47 37 51 38 45 32 21 41 39 
78 67 X  88 77 52 50 74 50 49 42 34 47 36 
67 57 73 70 78 42 55 72 60 58 44 33 37 37 
71 66 94 74 73 55 70 78 178 69 60 22 26 31 
63 67 67 54 65 46 62 78 73 62 42 35 39 44 
75 88 62 32 63 48 53 57 56 44 31  X 22 35 
43 85 69 69 55 29 46 64 55 52 34 23 23 32 
> 90 
68 58 71 79 69 64 71 84 71 60 52 47 31 36 
80 56 78 61 62 39 72 79 69 54 45 26 31 41 
51 56 162 59 82 70 78 80 69 60 42 39 69 32 
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Attachment 7 – Distribution of Cu, Fe, Mn and Zn (μg/g dry tissue) 
in different regions of ND patients. 
Brain 
region 
PD1 AD1 AD2 ALS 
Fe Mn Cu Zn Fe Mn Cu Zn Fe Mn Cu Zn Fe Mn Cu Zn 
1 247 1,1 17,0 38 198 0,8 12 67 280 1,2 36 89 190 0,9 17 64 
2a 348 0,7 15,5 54 356 0,8 13 64 352 1,2 33 87 166 0,6 17 45 
2b 294 0,9 14,0 70 323 1,0 12 58 267 1,1 27 81 198 0,8 17 56 
3a 932 2,0 18,0 54 1170 1,9 18 64 1268 3,7 45 88 310 1,7 24 49 
3b 1453 9,1 22,5 58 856 2,2 20 72 1539 4,4 52 95 1186 2,5 29 64 
3c 1660 1,5 20,8 71 1433 2,1 26 129 1410 4,0 31 66 619 1,3 23 40 
4 356 2,0 13,3 68 252 0,6 7 41 267 1,0 24 66 174 0,8 18 48 
5 295 1,8 13,4 93 505 0,8 12 72 327 1,6 27 87 256 1,4 14 68 
6 147 1,6 16,6 68 340 0,9 15 71 323 1,5 35 80 196 0,7 16 40 
7 433 1,6 17,6 54 312 1,1 16 63 506 1,6 34 67 284 1,0 21 58 
8 327 1,6 25,2 38 275 0,8 14 40 589 1,8 39 66 285 1,0 22 50 
9 111 1,0 5,5 30 102 0,6 9 29 145 1,0 21 44 50 0,6 10 32 
10 61 2,0 11,5 47 55 0,7 8 45 123 1,4 20 56 36 0,9 8 31 
11 471 0,9 16,4 37 351 0,6 24 47 360 0,9 27 41 339 1,0 29 45 
 
 
 
 
 
